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Globally, the HIV/AIDS epidemic has cost over 35 million lives and approximately a further 
37 million people are currently infected with HIV. In South Africa alone, more than 7 million 
people are HIV positive. Since the initiation of combination antiretroviral therapy (cART), 
viral replication can be supressed below the limit of detection by conventional testing. There 
is, however, no approved therapy for the cure of HIV. This is because HIV establishes viral 
reservoirs in memory CD4+ T-cells, where replication is low or arrested, allowing prolonged 
survival. Since there is little or no replication, a therapeutic strategy which targets the viral 
production and replication becomes ineffective and upon cessation of antiretroviral therapy a 
dramatic viral relapse occurs. The eradication of HIV, therefore, requires the targeted killing 
of the reservoir cells, or latency reversal followed by the prevention of further infection using 
cART.  
Targeting of cell-surface antigens for therapeutic purposes is the basis of immunotherapy. 
FDA-approved monoclonal antibodies such as Trastuzumab have been used to treat breast 
cancer via the human epidermal growth factor 2 (HER2) receptor. Immunotoxins (ITs) 
composed of an antibody fragment fused to apoptosis-inducing protein toxins targeting cell-
surface antigens have been used for therapy of refractory leukaemia. The anti-CD22 
recombinant IT Moxetumomab pasudotox based on Pseudomonas aeruginosa exotoxin A 
(ETA) has been FDA approved to treat hairy cell leukaemia. Moxetumomab pasudotox targets 
the antigen CD22 found on the surface of tumour cells. The HIV neutralizing VHH-nanobody 
J3, isolated from an immunised Llama has demonstrated anti-HIV properties against more than 
95 % of HIV strains in vitro. As part of an ongoing project to develop a J3-ETA IT, this work 
sought to produce a J3-SNAP fusion protein by osmotic stress expression in the presence of 
compatible solutes in the periplasmic space of E. coli. SNAP-tag is a self-labelling protein that 
covalently binds benzylguanine (BG)-modified substrates in a 1:1 stoichiometric ratio. When 
recombinantly fused to any protein of interest, SNAP-tag allows the stable labelling of the 
protein of interest of in vitro and in vivo imaging. The periplasmic space of bacteria has been 
reported as a dedicated compartment to express functional proteins of interest. Furthermore, 
osmotic stress expression in the presence of compatible solutes has been reported to result in 
up to a thousand-fold increase in protein yield for difficult to express proteins. This study 
ultimately aimed to understand whether a functional J3-SNAP or J3-ETA can be expressed 




In this study, a SNAP-tag-based fusion protein and an ETA-based IT were designed using J3, 
an anti-HIV-1 Env VHH-nanobody isolated from an immunised llama. Using the SnapGene® 
software (v.5.0.8, GSL Biotech LLC, USA), in silico design and cloning of an ETA-based IT 
J3-ETA and SNAP-tag-based fusion protein J3-SNAP was performed. Molecular cloning of 
designed open reading frames (ORFs) was performed into appropriate bacterial expression 
plasmid vectors. Plasmid vectors confirmed to contain the required ORFs by Sanger 
sequencing were transformed into E. coli BL21-DE3. Histidine-tagged J3-SNAP was 
expressed by osmotic stress in the presence of compatible solutes. J3-SNAP was purified by 
IMAC and assessed by SDS-PAGE and Western blot analysis. To ascertain the binding of J3-
SNAP to cells expressing HIV-1 Env in vitro, recombinant Env protein was transiently 
transfected into HEK293T-cells to generate an Env expressing cell line. Cell-surface binding 
of SNAP-Surface® Alexa Fluor® 488 -conjugated J3-SNAP on Env expressing HEK293T-
cells was assessed by confocal microscopy analysis. 
Results 
Successful expression of J3-SNAP in E. coli BL21-DE3 was confirmed by SDS-PAGE and 
Western blot analysis. The J3-SNAP fusion protein was subsequently purified by IMAC. 
Purified J3-SNAP was conjugated to the benzyl guanine-modified fluorophore SNAP-
Surface® Alexa Fluor® 488 and full-length conjugated protein was confirmed by 
combinations of SDS-PAGE and Western blot analysis. Cell-surface binding of J3-SNAP to 
HIV-1 Env-expressing HEK293T-cells was demonstrated in vitro by confocal microscopy 




Successful binding studies suggest using J3 to target HIV-1 Env. Accessing patient probes 
would allow for the confirmation of these results for future human applications. Future in vitro 
studies would need to confirm the selective elimination of Env expressing T-cells by J3-ETA 




Chapter 1. Introduction 
1.1 HIV and AIDS 
1.1.1 Origin and Epidemiology 
In 1981, three hospitals in the state of California (USA) were reported to have treated five 
homosexual men for Pneumocystis carinii pneumonia [1]. The U.S. Centers for Disease 
Control and Prevention then received numerous cases of opportunistic infections such as 
Pneumocystis carinii and Kaposi’s Sarcoma affecting men who engage in sexual intercourse 
with men. By 1982, more than 250 cases of severe immunodeficiency among homosexual men 
had been reported in America, France, and Spain. This rare disease, now named Acquired 
Immune Deficiency Syndrome (AIDS), was later reported to have affected haemophiliacs, 
people who injected drugs and patients that had received contaminated blood transfusions [2]. 
In 1984, the retrovirus Human Immunodeficiency Virus (HIV-1), isolated from an infected 
patient, was acknowledged as having caused AIDS [2], [3]. By 1990, the enzyme-linked 
immunosorbent assay (ELISA) blood test for HIV-1 had been approved by the U.S. Food and 
Drug Administration (FDA) and approximately 10 million people had been diagnosed with 
HIV-1 worldwide. This number would grow to approximately 37 million by 2017 [2]–[4]; [5]. 
The year 1997 saw a peak of new cases of HIV-1 with approximately 3.16 million people being 
reported worldwide. HIV-1-related deaths would later peak at almost 2 million in the year 2004 
[6]. By the year 2018 however, new infections had been reduced by 40 % since the year 1997. 
AIDS-related deaths had also declined by 56 % since the year 2004 and by 33 % since the year 
2010. The reduction in new infections and death is attributed to the development of 
antiretroviral therapy. It is estimated that only half of the people living with HIV are virally 
suppressed, despite almost two-thirds of people living with HIV being on antiretroviral therapy 
and 4 out of 5 people living with HIV-1 being aware of their status[4], [7], [8].  
Certain population groups are disproportionally affected by HIV/AIDS when compared to 
entire populations. The risk of contracting HIV-1 is more than ten times higher in transgender 
people and more than twenty times higher in sex workers, homosexual men and recreational  
intravenous drug users [4], [8], [9]. The occurrence of HIV-1 in the incarcerated population is 
projected to be five times that of the general population in North America, and up to fifteen 
times higher in North Africa and the Middle East. This is thought to be the result of key 
populations, such as recreational drug users, being concentrated in prisons, as well as the 
prevalence of unprotected consensual sex and sexual assault in jails and prisons [10]–[14]. The 
incidence has been shown to differ across continents and countries. High-income nations, such 
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as those in North America and Western Europe, report a sub 0.5 % prevalence of HIV-1, with 
9 in 10 infected individuals accessing antiretroviral therapy [8], [15]–[17]. Other regions that 
report low prevalence of HIV-1 include Latin America, where less than two million people 
were estimated to be HIV-1 positive, and only Bahamas, Belize, Guyana, Haiti, Jamaica, and 
Suriname report HIV incidence above 1% [8], [15], [16]. In 2012, North Africa and the Middle 
Eastern countries were reported to have approximately 260 000 people living with HIV-1. At 
0.1 %, the prevalence in this region is among the lowest globally [8], [15], [16]. Asia is the 
second most burdened region concerning the HIV-1 epidemic, with approximately five million 
people living with HIV-1 as of 2017 [8], [15], [16]. Despite a decrease in the global incidence 
of HIV-1 to less than two million new cases in 2017, sub-Saharan Africa has the highest 
incidence of HIV-1. HIV/AIDS remains one of the leading causes of death in this region. In 
2017, sub-Saharan Africa was reported to have accounted for two-thirds of all new HIV-1 
infections. Almost three-quarters of all people living with HIV-1 reside within sub-Saharan 
Africa. Three-quarters of all HIV-1-related deaths were also reported to be in sub-Saharan 
Africa [5], [7], [16], [18]. These variations are thought to be related to the following; (1) The 
prevalence rate of contraceptives. Regions where contraceptive rate is high report lower HIV-
1 incidence rates. The opposite is true for regions such as sub-Saharan Africa where the rate of 
contraceptive use is lower. (2) Availability of physicians. A positive correlation has been 
identified between the density of physicians and the incidence of HIV-1. (3) Religious and 
cultural practices. Regions such as the Middle East, where drug use, homosexuality, and 
extramarital sex are prohibited, report lower HIV-1 incidence rates. (4) Age of sexual initiation. 
Countries where girls initiate sex at a young age also report higher HIV-1 incidence rates. 
Lastly, (5) Education. Regions of the world that have a more educated population report lower 
HIV-1 incidence rates as populations are said to make smarter and safer decisions regarding 
their health [19]. As depicted in Figure 1.1 below, sub-Saharan Africa reported the highest 
number of deaths per 100 000 people in 2017. Contrary to the global estimates where 50% of 
HIV infected people are women, in sub-Saharan Africa, this figure rises to 59% [8]. Among 
other reasons, the disparity can be explained by the biological differences between men and 
women, where women have a larger mucus area that is susceptible to infection [20]. 
Furthermore, young women in particular, a more susceptible to contracting HIV. Both social 
and biological factors contribute to this disparity. A poorly developed cervix and low mucus 
production increase the risk contracting HIV. This risk is increased by gender inequality, a lack 
of autonomy for women in general and young women in particular, and poverty that drives 
women into situations where sexual intercourse is traded for money or goods [20]. Within sub-
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Saharan countries, the prevalence of HIV-1 varies between the countries as well as the 
states/provinces and district municipalities within each country [18], [21]. In South Africa, for 
example, provinces where most males (aged 15 – 49) are circumcised report lower HIV-1 
prevalence than provinces where most males are not circumcised. Furthermore, provinces, 
where males are circumcised in early adolescence, report lower HIV-1 prevalence than 
provinces where males are circumcised later in their adolescence or early adulthood [22].  
 
Max Roser and Hannah Ritchie (2020) - "HIV / AIDS". Published online at OurWorldInData.org. Retrieved from: 
'https://ourworldindata.org/hiv-aids' [Online Resource] 
Figure 1.1: Distribution of the annual number of HIV-related deaths per 100 000 people in 
2017. Estimates of global HIV-related deaths. Sub-Saharan Africa reported the highest burden of HIV/AIDS 
in 2017. Many countries reported incidences of less than 10 deaths per 100 000. With more than 200 deaths 
per 100 000, South Africa and Mozambique reported the highest death rate in 2017. 
 
1.1.2 Pathogenesis and disease progression 
HIV is a retrovirus belonging to the family Lentiviridae. There are currently two recognised 
species of HIV, namely HIV-1, and HIV-2. F. Barrй-Sinoussi and L. Montagnier received the 
Nobel Prize in Physiology or Medicine in 2008 for having discovered HIV-1 in 1984 and 
identifying it as the causative agent of AIDS [23]–[25]. HIV-2 was discovered in 1986 by F. 
Clavel and colleagues [26], [27]. The most common of the two HIV strains is HIV-1, which is 
further divided into several genetic subtypes (M, N, O, and P), of which the genetic group M 
(main) is most common. HIV-1 will be the focus if this study will therefore be referred to as 
“HIV”. HIV-2 has nine genetic groups (A-I). Within each genetic group, there are more than 
10 subtypes, such as with HIV-1 genetic group M (as reviewed [28]–[32]).  
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HIV is spherical with a cylindrical core and a lipid envelope (Figure 1.2). The single-stranded 
positive-sense RNA strand is covered by a protein shell. Three of the proteins encoded by the 
HIV genome include the group-specific antigen (gag), DNA polymerase (pol), and envelope 
protein (env). Env codes for the gp120 glycoprotein and gp41, both of which form the gp160 
complex (Env protein). The pol gene codes for the viral reverse transcriptase, protease, and 
integrase enzymes. The gag gene codes for the protein shell that encapsulates the viral genome. 
Additionally, the viral genome encodes regulatory genes that code for proteins which modulate 
the following: (1) The activation of reverse transcription (tat – trans-activator of transcription), 
(2) Regulation of viral structural protein transcription (rev – regulator of expression of virion 
proteins), (3) Prevention of antigen presentation on the surface of HIV infected cells, and (4) 
Elicitation of chemokine production that activates resting T-cells (Nef – negative regulator 
factor). Other genes encode proteins that suppress the synthesis of antiviral proteins (Vif – 
virion infectivity factor), stimulate transcription of viral RNA and translation of viral proteins 
(Vpr – viral protein R) and promote virion release (Vpu – viral protein U)  in ref [33]–[36].  
  
Figure 1.2: Schematic diagram of the HIV particle. HIV is a spherical lentivirus composed of a lipid 
bilayer membrane. Gp120 and gp41 are found on the surface and facilitate integration into host cells. Matrix 
protein covers the inner capsid. Capsid protein covers viral proteins and ribonucleic acids (RNA). The capsid 
of the virus encloses the viral genome (two RNA strands) as well as the reverse transcriptase, integrase, and 
protease enzymes. (adapted from [37]) 
 
HIV infection commences when the the viral membrane protein, cyclophilin-A, attaches to the 
human protein heparan [38], [39]. This weak association precedes the binding of HIV 
glycoprotein gp120 to CD4 (cluster of differentiation 4) molecules predominantly found on 
16 
 
CD4+ T-cells and, less commonly, on macrophages, dendritic cells, monocytes, glial cells and 
astrocytes. When gp120 attaches to CD4 molecules, a conformational change in the CD4 
molecule results, allowing gp120 to also bind to the chemokine co-receptors CCR5 (C-C 
chemokine receptor type 5) or CXCR4 (C-X-C chemokine receptor type 4) (Figure 1.3 – step 
1). The fusion peptide is exposed, which then penetrates the membrane of the host cell, 
followed by the formation of a fusion pore. Membrane fusion is facilitated by the six-helix 
bundle of gp41 which draws the two membranes closer to one another. The core of HIV enters 
the target cells while the envelope and its proteins remain on the surface of the host cell [40]–
[47] (Figure 1.3 – step 2). In the cytoplasm of the host cell, uncoating of HIV occurs, followed 
by synthesis of proviral DNA from HIV genomic RNA, mediated by the reverse transcriptase 
enzyme [47]–[50] (Figure 1.3 – step 3). Viral DNA is then transported to the nucleus by the 
pre-initiation complex, where the viral integrase enzyme incorporates proviral DNA into 
transcriptionally active regions of the host genome [47], [51]–[54] (Figure 1.3 – step 4). 
Transcription of viral RNA in the host cells occurs when T-cells are activated, followed by the 
activation of pro-transcription factors including nuclear factor kappa-β (NF-κβ), Tat, and 
positive transcription elongation factor (P-TEFb) [55]–[60] (Figure 1.3 – step 5). The HIV 
protease then processes viral polyproteins before viral morphogenesis in the cytoplasm, 
followed by virions leaving the cell in exosomes by budding [61]–[67] (Figure 1.3 – steps 6-
7).  
 
Figure 1.3: HIV replication cycle in host cells. HIV binds the CD4 receptor on host cells. 1. Binding: 
The CD4 receptor undergoes a conformational change and draws the virus close to the cell. 2. Membrane 
fusion: Coreceptors CCR5 or CXCR4 interact with the virus and the virus enters host cells by membrane 
fusion. 3: Reverse transcription: Following the uncoating of HIV within the host cell, the synthesis of viral 
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DNA from viral RNA is then catalysed by reverse transcriptase. 4. Integration: Integrase catalyses the 
incorporation of viral DNA into the host genome. 5. Transcription: HIV then uses host mechanisms to 
transcribe proviral DNA to make viral RNA and essential viral proteins. 6. Assembly: Viral RNA and proteins 
assemble at the surface of the host cell. 7. Budding: Immature virions bud off from the host cell. 8. Maturation: 
Protease cleaves viral proteins into their active forms and virions can now infect new cells. (adapted from [68]). 
 
HIV uses a variety of mechanisms to establish infection and progress from acute to chronic 
infection while avoiding the host's immune system. Innate immune evasion by HIV is aided, 
in part, by the error-prone nature and poor proofreading ability of HIV RNA polymerase which 
results in genetic variability [69], [70]. HIV typically enters the body through mucosal barriers. 
It penetrates through intercellular spaces before reaching its target cells within the mucosal 
barrier where the infection of HIV is typically established [69]. Upon infection, the infected T-
cells migrate to secondary lymphoid tissue where they interact with B-cells and T-helper cells. 
Secondary lymphoid tissue has a high concentration of HIV susceptible follicular T-helper 
cells. It is in secondary lymphoid tissue where HIV replicates and infects susceptible cells, 
resulting in a substantial increase in viremia during acute infection [69]. The functions of 
macrophages, natural killer (NK) cells, and dendritic cells (DC) are altered during HIV 
infection due to dysregulation of pro- and anti-inflammatory cytokines [69], [71]. The 
inhibition of interferon production during HIV infection results in reduced NK-cell function. 
Heightened NK-cell activity has been linked with increased resistance to HIV infection, and 
an increase in plasma NK-cell frequency has been shown to reduce HIV viremia, thus the 
dysregulation of NK-cell function is crucial for disease progression [69], [71], [72]. In the gut 
mucosa, NK-cells function to promote the survival of the epithelial cell lining. The integrity of 
gut mucosa is critical for the prevention of the translocation of gut microbes which increases 
immune activation and subsequent immune exhaustion during HIV infection. Together with 
NK-cells, T-helper 17 (Th17) cells help preserve the integrity of gut mucosa. Th17 cells are, 
however, susceptible to HIV infection due to the expression of the CD4 receptor on their 
surface. During HIV infection, these cells are depleted and must be regenerated. The high 
turnover number of CD4+ T-cell production results in the production of short-lived T-cells and 
is not conducive to Th17 cell production. This results in a compromised intestinal lining and 
subsequent intestinal microbe translocation, immune activation [73]–[78].  
Chronic HIV is characterised by immune activation as a result of gut microbe translocation, 
evidenced by reduced circulating lipopolysaccharides during cART. Disease progression is 
better depicted by immune activation rather than viral load [74], [79]. Immune dysregulation, 
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T-cell exhaustion, and subsequent immune exhaustion in chronic HIV infection can leave 
victims of HIV susceptible to a myriad of opportunistic infections. The patient is said to have 
acquired immunodeficiency syndrome (AIDS) at this stage. The opportunistic infections 
include bacterial, fungal, protozoal and viral infections. Neoplasms such as lymphoma, 
squamous cell carcinoma and Kaposi sarcoma have been frequently reported [80]–[83]. 
Oropharyngeal candidiasis (OPC), cryptococcal meningitis, Pneumocystis carinii pneumonia 
(PCP), cerebral toxoplasmosis and tuberculosis are among the most frequently reported AIDS-
associated illnesses. Approximately 90 % of HIV-infected individuals are thought to suffer 
from mouth sores at some stage of the disease, mainly due to OPC. Candida albicans is 
typically the cause of OPC, affecting the soft buccal mucosa [84]–[86]. C. Albicans is, 
however, the less severe of the AIDS-defining fungal infections. Cryptococcus neoformans is 
a yeast infection that rarely causes infection in healthy individuals, but in immunocompromised 
individuals results in cryptococcal meningitis and meningoencephalitis. Mortality caused by 
cryptococcal meningitis in poorer countries remains higher than that of developed regions (43 
% and 25 % respectively) [87]–[90]. Mycobacterium tuberculosis (MTB) dominates the list of 
bacterial infections of which HIV infected individuals are at high risk. Annually, more than 
one million HIV-positive people contract active MTB, with sub-Saharan Africa contributing 
to three-quarters of all new MTB cases [91], [92]. Much like the previously mentioned 
opportunistic infections, exposure of healthy individuals to the infectious agent is common and 
results in latent asymptomatic infection due to a cell-mediated immune response that prevents 
disease manifestation [93]. Though antiretroviral therapy has significantly resulted in reduced 
incidence and mortality due to pulmonary TB, it remains the leading cause of death among 
HIV infected people in sub-Saharan Africa [94]. After being responsible for more than 20 000 
new cases at the beginning of the epidemic, the first AIDS-defining disease to be identified 
was PCP. It was the diagnosis of several homosexual men with PCP that led to the discovery 
of AIDS [95]. Since the initiation of combination antiretroviral therapy (cART), the number of 
reported cases worldwide has since been reduced significantly [95]. PCP infection only 
progresses to a diseased state following severe immunosuppression. [95]–[98]. The most 
common central nervous system (CNS)-affecting opportunistic disease after cryptococcal 
meningitis is the protozoal infection cerebral toxoplasmosis [99]–[101]. Causing multifocal 
lesions, encephalitis and the formation of cysts in many organs, cerebral toxoplasmosis has 
been found in some studies to be an AIDS-defining illness in approximately 75 % of the cases 
[99]–[102]. Cerebral toxoplasmosis is typically due to toxoplasma gondii and is generally 
ingested through the consumption of oocysts-contaminated foods or water [100], [102]. Cell-
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mediated immunity involving T-cells, macrophages, (interleukin) IL-2, and interferon γ all 
function in tandem to prevent the progression to a diseased state in healthy individuals 
following exposure to pathogens. In immunocompromised HIV positive individuals, the 
components of the immune system responsible for controlling the infection are impaired or 
dysfunctional [100]–[102]. Furthermore, in healthy individuals, toxoplasma gondii is 
controlled but not eliminated, allowing disease progression should the immune system ever be 
compromised [102]. Though early cART has been shown to improve survival and reduce the 
relapse of toxoplasmosis, the disease remains among the most common cerebral opportunistic 
pathogens in both developing and developed nations [99], [101]. Antiretroviral therapy has 
therefore played a vital role in mitigating or, in some cases, preventing AIDS-associated 
illnesses. 
1.1.3 Antiretroviral Therapy 
In 1987, the British pharmaceutical company GlaxoSmithKline was awarded FDA approval 
for the first therapy against HIV, Zidovudine. A nucleoside analogue initially trialled as an 
anticancer agent, Zidovudine was found to impede the viral enzyme reverse transcriptase,  
preventing the synthesis of proviral DNA and subsequent synthesis of new virions [103]–[105] 
In 1996, another class of antiretrovirals would receive FDA approval: Protease inhibitors (PIs) 
that inhibited HIV maturation were being used together with nucleoside reverse transcriptase 
inhibitors (NRTIs) such as zidovudine [103], [106]. A year later, in 1997, non-nucleoside 
reverse transcriptase inhibitors (NNRTIs) would receive FDA approval [107]–[110].  
Antiretrovirals are strategically used in cART to inhibit HIV pathogenesis at the following 
stages; (1) entry, (2) reverse transcription, (3) integration, and (4) maturation.  One of the 
newest classes of ARVs is viral entry inhibitors. The FDA approved drug, Maraviroc, is a 
CCR5 antagonist that binds to a hydrophobic transmembrane pocket on the CCR5 receptor, 
resulting in conformational changes that prevent interaction with gp120 [103], [111], [112]. 
The first class of antiretrovirals to be approved, NRTIs, is a class of nucleoside substrates that 
cause termination of reverse transcription. They may be guanosine, thymidine, or cytidine 
analogues, but all lack a 3’ hydroxyl group required for the formation of a 3’-5’ phosphodiester 
linkage which links nucleotides together during DNA synthesis. The pre-integration complex 
which integrates the viral genome into the host cell, requires the complete genome. Termination 
therefore attenuates progression of HIV [103], [113], [114]. NNRTIs are non-competitive 
inhibitors of reverse transcriptase with the same effect as NRTIs. NNRTIs bind to a 
hydrophobic pocket near the enzyme active site, inducing a conformational change that reduces 
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enzyme activity. FDA-approved examples include Etravirine, Delavirdine, Efavirenz and 
Nevirapine [103], [110], [115]. Integrase inhibitors such as Raltegravir prevent the irreversible 
step of viral genome integration into the host genome which is responsible for making HIV 
infection a lifelong illness. Integrase is responsible for 3’- end processing of viral DNA and 
subsequent strand transfer via the pre-integration complex. Integrase inhibitors prevent viral 
genome integration by binding to the pre-integration complex [103], [116], [117]. Introduced 
in 1995, protease inhibitors such as ritonavir, saquinavir, and indinavir inhibit HIV maturation 
by binding to the enzyme active site and inhibiting the HIV aspartyl protease enzyme 
responsible for cleaving the HIV gag and gag-pol polyprotein into the shorter functional 
proteins such as protease, reverse transcriptase, RNase H, and integrase [118], [119]. This 
multi-pronged approach was the basis of cART, utilizing a combination of three forms of 
therapy, NRTIs, NNRTIs, and PIs, to combat HIV. This combination would later be shown to 
reduce viremia to below detectable levels [103]. Owing to the side-effect profile of PIs, this 
class has since been used less frequently with integrase inhibitors taking preference [119]–
[121].  
1.1.4 Barriers to a cure 
Despite the improvements in antiretroviral therapy, HIV remains a burden on society. While 
antiretroviral therapy can reduce viremia to below detectable levels, it is not curative. cART 
must be maintained for life in to prevent a relapse of viremia. This is because, during the acute 
stage of infection, HIV establishes reservoirs in multiple CD4+ T cell subtypes and can, 
therefore, persist in a latent or transcriptionally active state. Long-lived memory CD4+ T-cells 
typically house a majority of latent integrated HIV provirus [122]–[126]. Mechanisms 
undertaken by HIV to regulate the transcription of the viral genome include DNA methylation, 
as well as histone deacetylation and methylation [127]–[132]. These repressive epigenetic 
modifications make DNA less accessible to the transcription factors, NF-κβ and pTEFb, which 
are also downregulated or absent during latency. Reduced access of transcription factors to 
proviral DNA means viral mRNA cannot be transcribed and subsequent viral protein 
translation is prevented. Antiretroviral therapy is therefore rendered inactive against latent 
infection, as it targets different stages of an actively replicating virus [130], [132]. CD4+ T-
cells harbouring latent HIV provirus are thought to be the main barrier to attaining a functional 
cure. Targeting T-cells harbouring latent HIV provirus requires a deeper understanding and an 
accurate estimation of the proportions of T-cells harbouring latent provirus. However, not all 
CD4+ T cells contain integrated and replication-competent provirus. It is estimated that latently 
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infected cells represent not more than 0.1 % of all CD4+ T cells [133]. Strategies to a cure 
require an accurate means of estimating the true size of the viral reservoir. Several strategies 
have been undertaken to estimate the size of the reservoir and each has its advantages and 
disadvantages. For example, an assay that quantified total HIV DNA within a host cell would 
include both integrated and non-integrated viral DNA, with the latter being up to 100-fold 
higher in concentration compared to the former. As a result, this technique would most 
probably underestimate the size of the reservoir. Quantitative viral outgrowth assays, which 
quantify active viruses, are thought to underestimate the size of the reservoir considering the 
estimation that at any given time since only 1 % of the replication-competent reservoir is 
actively replicating. The sequencing of an integrated provirus may be the best approximation 
of the size of the reservoir. However, this technique, much like the viral outgrowth assays, is 
financially unfeasible, time-consuming, and labour-intensive (as reviewed [134]).  
The early initiation of cART has been shown to greatly reduce the size and the complexity of 
the reservoir [135], [136]. Conversely, Goonetilleke et al. (2019) postulated that cART can 
contribute to the formation of a stable reservoir. Following the depletion of CD4+ T-cells 
during the acute phase of the HIV infection, the introduction of cART replenishes the CD4+ 
T-cell population which subsequently transitions to memory CD4+ T-cells vulnerable to 
infection by HIV [137]. Other authors have postulated that stable reservoirs are established 
from cell proliferation rather than from new infections [137]–[143]. The composition of the 
reservoir is thought to be largely influenced by a phenomenon known as clonal expansion. 
Viremia circulating the blood of a chronically infected HIV patient shows genetic variations 
that result over time. Only a sample of these clones will be found in the genital tract, and the 
selection pressure only increases concerning viremia presence in the transmission fluid of the 
donor [144], [145]. There is typically no genetic variation in the blood of a newly infected 
individual due to the tough selection pressure that usually allows only one clone to overcome 
the barriers presented by the recipient's mucosa during infection [144], [145]. Heterogeneity of 
HIV is then restored upon disease progression. Studies have found that when persons with a 
heterogeneous population of viremia are treated with cART for a prolonged period the 
heterogeneity of the viremia is reduced, and the population can be dominated by a single clone 
or two. This is known as clonal expansion. The infection of multiple cells by a single dominant 
viral species may lead to genetic similarities. However, identical sequences arise from a clonal 
expansion during cART and contribute to the maintenance of a stable reservoir [138]–[140], 
[142], [143]. Upon analysis of the site of the viral genome in clones that persist during cART, 
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it was observed that clonal expansion was common when integration of the viral genome 
occurred in active transcription units [146]. The maintenance of a stable reservoir is the largest 
barrier to an HIV cure [122]–[126]. 
1.1.5 Emerging therapeutic strategies 
Given the barriers to a functional cure for HIV, several strategies have been undertaken, aiming 
to undo the mechanisms by which HIV achieves and maintains latency. Strategies involve early 
initiation of cART, gene therapy, immune therapy, and the “Shock and Kill” strategy [147]–
[150]. Minimizing the size of the viral reservoir is an essential step in the pursuit of eliminating 
HIV. Early initiation of cART has been shown to reduce the size of the reservoir and preserve 
the immune system. Early initiation of cART has also been shown to increase the rate at which 
the viral reservoir decays [135], [150]–[152]. The extent to which the CD8+ T-cell population 
and function can be restored depends partially on how early cART is initiated [153]. CD8+ T-
cells are thought to play an important role in the eradication of viral reservoirs, owing to their 
ability to kill viruses, particularly during acute infection. CD8+ T-cells become dysfunctional 
in the chronic state, evidenced by reduced T-cell differentiation and proliferation, reduced 
cytolytic activity, and reduced signalling through interferon-γ, tumour necrosis factor-α, 
interleukin-2, and macrophage inflammatory protein-1β [153]–[156]. The ineffective T-cell 
response in patients with or without cART as well as insufficient T-cell restoration results in 
HIV viral rebound. Reservoir clearance, therefore, requires the restoration of CD8+ T-cell 
function [156]. As early as 1998, canarypox HIV vaccines were shown to induce a cytotoxic 
T-lymphocyte (CTL) response [157]. The CTL response was further improved by 
immunisation with both the live canarypox vaccine expressing gp120 and gp41 when co-
immunised with recombinant gp120 [158], [159]. Furthermore, vaccines are yet to be curative. 
Though early vaccines demonstrated immunogenicity, elucidating an antibody and CTL 
response, they ultimately fell short, owing to their inability to prevent infection [156] [160].  
In response to HIV infection, some patients have developed  broadly neutralizing antibodies 
(bNAbs) that can neutralise  HIV by target mainly five regions on the HIV Env protein; (1) the 
CD4 binding site on gp120, (2) second and third variable loops (V2 and V3), (3) proteoglycan 
moieties, (4) membrane-proximal external region (MPER) of the transmembrane domain of 
Env, and (5) the gp120-gp41 interface [161], [162]. Several antibodies binding to different 
regions of the same epitope have been isolated for all the above-mentioned epitopes, each 
depicting varying specificity for HIV isolates from patient samples [163] [164]. In addition to 
their ability to neutralise a variety of HIV strains, bNAbs have also been shown to prevent 
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infection across different animal models and routes of infection. When used in combination, 
bNAbs targeting various epitopes of Env have demonstrated and maintained efficient 
suppression of viremia in animal models and humans [164] [165]. In addition, the half-life 
plays a critical role in HIV neutralization. Studies have shown that when bNAbs have been 
modified to have increased affinity for neonatal Fc receptors, the half-life of the bNAbs was 
prolonged with subsequent sustained protection against HIV [164]. While non-neutralizing 
antibodies (nNAbs) have also been studied for their anti-HIV effects, they have fared poorly. 
nNAbs show poor antigen-binding activity, viral suppression, and an inability to prevent 
further infection in animal models [166], [167]. Their inability to induce antibody-dependent 
cell cytotoxicity (ADCC) and their narrow specificity make nNAbs less favourable compared 
to bNAbs [168].  
To date, the only means of therapy to have successfully cured HIV is hematopoietic stem cell 
transplantation. An HIV-positive patient diagnosed with leukaemia received hematopoietic 
stem cells from a donor with a rare CCR5Δ32 mutation that results in shortened CCR5 that is 
not translocated to the cell surface. HIV, therefore, has no co-receptor with which to react and 
cannot infect the cell in question [169] [170]. Two patients from Boston also received 
hematopoietic stem cells. The donors, however, did not have the CCR5Δ32 mutation. Despite 
the reduction of the size of the viral reservoir, viral rebound was observed within a year [171]. 
More recently, an HIV positive patient in London received allogeneic stem-cell transplantation 
with cells containing the CCR5Δ32 mutation and has been able to live free of cART with no 
detectable viremia [172]. This has sparked interest in gene therapy studies aimed at removing 
the CCR5 gene in the hopes of preventing HIV infection. Genome editing using zinc-finger 
nucleases, transcription activator-like effectors, and clustered regularly interspaced short 
palindromic repeats (CRISPR)-Cas9 technology have been identified as possible means of 
elimination of CCR5 in CD4+ T-cells, and possibly stem cells, to make CD4+ T-cells and other 
susceptible cells resistant to HIV infection [164], [173]–[175]. The most prominent strategy 
for combatting HIV is the “Shock and Kill” strategy. This strategy involves the reversal 
“shock” of latent infection in long-lived memory CD4+ T-cells using latency-reversing agents. 
Latency reversal is mediated by agents such as protein kinase C (PKC) agonists, histone 
deacetylase inhibitors (HDACi), histone methylation inhibitors (HMTi), DNA 
methyltransferase inhibitors (DNMTi), among others. PKC modulates the levels of the 
transcription factor NF-κB, which subsequently contributes to the transcription of HIV proviral 
DNA. Epigenetic modifications are one of the most prominent means of latency achieved by 
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HIV. HDACis, DNMTis, and HMTis act by reducing the methylation of histone proteins and 
DNA, allowing access of transcription factors to the target loci housing HIV proviral DNA. 
The effectiveness of latency reversing agents (LRAs) can be improved by using multiple LRAs 
in combination with cART. Latency reversal must then be coupled with other means of therapy 
such as cART to prevent more infections, as well as bNAbs capable of eliminating viremia and 
eliciting an ADCC response (as reviewed [176]–[178]). 
1.2 Immunotoxins 
1.2.1 Design of Immunotoxins (ITs) 
In the fight against HIV, there may be some lessons that can be learned from the fight against 
cancer. Antibodies and antibody technology have taken a lead role in the fight against cancer 
with more than one hundred antibody-based being approved for clinical use. The list of 
approved therapies includes monoclonal antibodies and ITs [179]–[181]. An IT is a fusion 
protein comprised of an antigen-binding domain fused either chemically or recombinantly to 
an effector domain in the form of a protein toxin. The binding domain is typically a growth 
factor or an antibody [182]–[185]. The first generation of ITs composed of whole monoclonal 
antibodies fused to full-length plant or bacterial protein toxins as effector domain. This format 
suffered major drawbacks including lack of specificity, off-target effects, and the combination 
was unstable [183]–[186]. Second generation ITs sought to combat some of these drawbacks 
by removing the binding domain in the toxins as they served no function since the targeting 
domain was already the antibody. Furthermore, this reduced bystander effects as toxins could 
only enter cells when there was an epitope-paratope interaction between the antibody fragment 
and the cell-surface antigen of the target cell [183]–[186]. Due to the size of the full-length 
antibody and that of the toxin, tumour penetration remained an issue, and conditions like 
vascular leak syndrome and pleuritis resulted. In attempts to mitigate some of these issues, T-
cell and B-cell epitopes were mutated on the toxin. More importantly, antibody the variable 
regions (Fab) of antibodies were used rather than whole antibodies. As advanced as ITs have 
become, they still employ bacterial toxins. First, second and third generation ITs are depicted 
in Figure 1.5. The latest generation of ITs employs the effector domains of human cytolytic 
and pro-apoptotic enzymes such as granzymes and angiogenin [183]–[186].  
Immunoglobulins or antibodies are heterodimeric protein structures containing two identical 
heavy chains (50 kDa) and two identical light chains (25 kDa) in the form of β-barrels, linked 
together by disulphide bridges [187]–[189]. IgG is the most abundant of the immunoglobulin 
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classes that naturally occur in human serum, accounting for up to 20 % of serum proteins [187], 
[189]. The light chain of IgG comprises the constant light chain (CL) and a variable light chain 
(VL). The heavy chain comprises a variable heavy chain (VH), and three constant heavy 
regions (CH1. CH2, and CH3). VH, CH1, VL, and CL make up the Fab region of the antibody 
which is linked by a hinge region to the fragment crystalline (Fc) region [189]. The hinge region 
confers flexibility to the immunoglobulins and is a function of the length of the amino acid 
sequence in this region. Within a class of antibodies such as IgG, hinge regions may vary 
between 62 amino acids (IgG3) and 12 amino acids (IgG2 and IgG4) [189]. The variable 
domain (Fv) of the immunoglobulin, composed of VH and VL, confers antigen recognition and 
binding capabilities [187]–[189]. Each variable domain (VH or VL) is composed of four 
relatively constant framework regions (FR) and three highly variable complementarity-
determining regions (CDR) [187]–[189]. Three CDR regions from VH and three CDR regions 
from VL make up the antigen-binding site [188]. The constant regions of IgG antibodies confer 
the ability to elicit an immune response through complement activation and interaction with Fc 
receptors on Fc receptor-expressing cells. Upon opsonization of an antigen,  the interaction of 
IgG with Fc receptors results in phagocytosis or some form of antibody-dependent cell-
mediated cytotoxicity [187]–[189]. Figure 1.4 depicts common antibody fragments. Fab 
antibody fragments are composed of just the Fab region of the antibody, stabilised by linkers 
and disulphide bridges. Fv antibody formats are either stabilised by disulphide bridges (dsFv) 
or by a linker (scFv). Llama IgG has a unique, single-domain antibody format with an Fc 
domain linked to a heavy chain (VHH) [187]. 
 
Figure 1.4: IgG antibody fragments. Human IgG is 150 kDa in size. IgG is composed of an Fc region 




Two of the most well-studied IT effector domains are diphtheria toxin (DT) and Pseudomonas 
aeruginosa exotoxin A (ETA). DT is composed of an enzymatic domain and a binding domain. 
The binding domain of DT-based fusion proteins includes cytokines (IL-2, and IL-3) or 
antibodies (CD3 scFv, CD22 scFv, CD19 scFv) [190]. The low pH of endosomes allows for 
the infolding of DT. The enzymatic domain is then translocated into the cytosol through a 
channel formed by a TH8 and TH9 hairpin. Apoptosis is induced when the elongation factor 2 
undergoes ADP ribosylated by nicotinamide adenine dinucleotide, causing cessation of protein 
translation (as reviewed [183], [185]). DT-based ITs have been clinically successful, leading 
to FDA approval of IL-2Receptor-targeting DT toxin Danileukin diftitox for treatment of 
cutaneous T-cell lymphoma [183]. Moxetumomab pasudotox is an IT that has also received 
FDA approval for the treatment of hairy cell leukaemia. Moxetumomab pasudotox is a BL-21-
targeting IT that employs ETA as its protein toxin. Moxetumomab pasudotox comprises of a 
truncated ETA that is recombinantly fused to the anti-CD22 (Fv) antibody [191]. ETA is 
composed of a binding, translocation, and catalytic domain (Figure 1.5). ETA enters a cell by 
interaction with the macrotubulin receptor and is internalised into endosomes, where the 
protease furin, cleaves domain 2. ETA is then translocated to the cytosol where it facilitates 
the ADP ribosylation of EF-2. ED-2 is then irreversibly inactivated, leading to the cessation of 
protein translation and subsequent apoptosis [183], [192], [191]. DT and ETA have been used 
to develop other ITs. Cytokines IL-2, IL-3, and IL-4 have been used as the targeting domains 
of both DT-based and ETA-based ITs in immunotherapy. Antibodies targeting CD3, CD7, 
CD19, CD20, CD22, and epidermal growth factor receptor (EGFR) fused to both ETA and DT 
have been developed as ITs for potential cancer therapy [190].  
A 
is an 80 kDa heterodimer composed of an Fc region and a heavy chain. Single-chain variable fragments (scFv) 










Figure 1.5: Evolution of Immunotoxins. (A) Diphtheria toxin and Pseudomonas aeruginosa Exotoxin A 
are composed of 3 domains; Binding, Translocation, and catalytic domains. (B) First-generation immunotoxins 
(IT) were composed of full-length monoclonal antibodies conjugated to toxins. Second generation ITs were 
composed of full-length antibodies with toxins missing the binding domain. Third generation ITs were 
composed of antibody fragments such as Fab, disulphide-stabilised single-chain variable fragments (dsFv), or 
single-chain variable fragments (scFv). (Adapted from [184]) 
 
1.3 Gp120 
Since the late 1980s, researchers have attempted to use ITs to combat HIV. Initially, researchers 
used truncated ETA fused to the CD4 molecule to specifically target gp120 which is found on 
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the surface of HIV infected CD4+ T-cells. Though CD4-ETA ITs showed the specific killing 
of target cells in culture, the efficacy did not translate to phase 1 clinical trials [193]. Instead, 
the researchers found that CD4-ETA resulted in hepatotoxicity, or resistance to the IT 
developed rapidly [194]–[197]. ETA-based ITs composed of murine anti-gp120 monoclonal 
antibodies and anti-gp120 antibodies isolated by phage display technology have demonstrated 
specificity for HIV infected cells [198], [199]. Taken together, this shows the potential of 
gp120 as a molecular target for HIV infected cells. 
The HIV envelope glycoprotein (Env) is synthesised as monomers in the rough endoplasmic 
reticulum (RER). The monomers then oligomerise in the ER before being trafficked to the 
Golgi apparatus. Furin cleaves gp160 into the cell-surface gp120 and transmembrane gp41. 
Glycoproteins gp120 and gp41 remain in complex owing to non-covalent interactions. The 
gp120/gp41 complex is then transported to the cell membrane to be added to budding virions 
(Figure 1.3). At the plasma membrane, other than incorporation into budding virions, gp120 
may be shed or the whole complex may be endocytosed into early endosomes. The complex 
can be recycled back to the cell membrane or may move into late endosomes and then 
lysosomes for degradation [200]–[202]. The rapid recycling process is thought to help evade 
the host immune system [200]. 
Gp120 (Figure 1.6) comprises conserved sites including the CD4 binding site, a less constant 
co-receptor binding site, a variable loop (V3), and hypervariable loops 1 and 2 (V1 and V2) 
[200], [202]. The variable domains are not involved in binding interaction with CD4 but are 
primarily targeted by antibodies [202]. Upon interaction with CD4, gp120 changes 
conformational and exposes the co-receptor binding site. Gp41 is responsible for anchoring 
Env into the host cell membrane and owes this to its fusion peptide which is typically hidden 
within the complex and is exposed when the conformation of gp120 is altered. The fusion 
peptide penetrates the host cell membrane, causes destabilization and forms a fusion pore. A 
six-helix bundle, formed by hydrophobic regions of gp41 known as heptad-repeat regions 1 





Figure 1.6: Gp120 schematic diagram showing three gp120 subunits. HIV glycoprotein gp120 schematic 
diagram depicting CD4 binding site, variable loops 1, 2, and 3 (V1, V2, V3), and coreceptor binding sites. 
(adapted from [203]) 
 
1.4 Nanobody targeting of the CD4 binding region on gp120 of the Env protein 
Naturally occurring antibody formats unique to camelids are composed of an Fc region and a 
variable heavy chain only [187]. Their sequence similarity to humans is predicted to result in 
low immunogenicity and is expected to be relatively easy to humanise. Similar to other heavy 
chain domains, the VHH fragment of the Fab domain is composed of three CDR regions but 
with a few seemingly significant differences. VHH nanobodies have a longer CDR3 region and 
lack a hydrophobic region as there is no accompanying VL. The extended CDR3 region is 
thought to allow VHH nanobodies to reach into antigen cavities that other antibody formats 
may be unable to achieve. Some rare human bNAbs such as PG19, found to bind conserved 
epitopes of the HIV Env protein have also been found to have long CDR3 regions [204]. pH 
stability and improved tissue penetration further add to the advantages of VHH nanobodies, 
despite the size also being a disadvantage concerning its contribution to a shorter serum half-
life [205]. VHH nanobodies have been mainly used in the development of cancer diagnostics 
and therapeutics. VHH-based ETA ITs have demonstrated promising anti-cancer effects 
against T-cell lymphoblastic leukaemia in mice [206], [207].In recent years, VHH nanobodies 
have been raised, capable of neutralizing various strains of HIV. Of interest, J3, a VHH that 
was reported to neutralise more than 95 % of one hundred HIV strains tested, and six simian-
HIV pseudoviruses. J3, a novel VHH generated by the immunisation of camelids with gp140 
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trimers was selected based on its ability to neutralise pseudoviruses from several HIV subtypes 
and strains, by targeting the conserved CD4 binding region on gp120. [208].  
1.5 SNAP-tag technology 
In 2003, scientists from the Swiss Federal Institute of Technology Lausanne described the 
repurposing of a DNA-repair enzyme for covalent labelling of recombinant fusion proteins in 
vivo. In DNA repair, the DNA repair enzyme O6-Alkylguanine DNA alkyltransferase (AGT) 
catalyses the transfer of an alkyl group from its substrate to a cysteine residue on AGT. 
According to Keppler et al. (2003), AGT reacted to its substrate O6-Alkylguanine-DNA, but 
also to O6-benzylguanine with a substituted benzyl group. As a result, SNAP-tag was 
developed. SNAP-tag is a self-labelling protein capable of reacting covalently in a 1:1 
stoichiometric ratio with any benzylguanine (BG)-modified substrate. This may include 
fluorophore or small molecule toxin to which a benzyl group has been attached to its cysteine 
145 residue (Figure 1.7) [209]–[211]. In therapeutics, the use of antibodies to deliver small 
molecule toxins to tumours by mere conjugation to cysteine or lysine residues, as is done in 
several antibody-drug-conjugates (ADCs), has several drawbacks. ADCs exhibit heterogeneity 
concerning drug-to-antibody ratios such that reaching required cytotoxic payloads may be 
difficult due to the uneven number of drug molecules to antibodies. ADCs have also been 
reported to be unstable as heterogeneity can be further aggravated by toxin conjugation at 
different sites [212]–[214]. SNAP-tag, therefore, provides a more stable alternative to the 
delivery of quantifiable cytotoxic payloads to target cells. The small molecule toxin can, as 
previously mentioned, be substituted for a fluorophore, arming the technology with far-




Figure 1.7: Schematic diagram of VHH antibody fragment recombinantly fused to SNAP-tag. The 
reaction of the SNAP-tag-based fusion protein with a benzylguanine-modified substrate (green) (small 
molecule toxin or fluorophore). SNAP-tag (blue) is recombinantly fused to VHH nanobody (purple). (Adapted 
from [212]) 
 
1.6 Expression of recombinant proteins 
Several expression systems can be used to produce recombinant proteins based on the 
advantages and disadvantages of each system. Mammalian and bacterial host cells are most 
commonly used [216]. The expression of recombinant proteins in bacteria presents advantages 
such as the rapid growth of bacterial cells, with a doubling time of approximately 20 minutes 
under optimal conditions [217]. Bacterial cell culture is relatively inexpensive. E. coli genetics 
are well-studied and are hence easily manipulated to achieve desired outcomes. Strains of 
bacteria are genetically engineered to achieve high yields of protein. However, bacterial protein 
expression has its drawbacks. Bacteria cannot produce large and complex proteins as they are 
unable to post-translationally modify proteins. In addition, full-length antibodies, for example, 
cannot be produced in bacteria. Codon bias is another hurdle that must be overcome when 
aiming to produce recombinant proteins in bacteria. Proteins produced in bacteria can be locked 
in inclusion bodies, making the extraction complicated (reviewed in [216], [218]–[223].) 
Some of the challenges faced when producing recombinant proteins in bacteria have been 
addressed. Enzymes such as glutathione reductase have been added to the genome of the 
bacteria to increase disulphide bond formation. Bacteriophage T7 promoter and RNA 
polymerase have been added to increase the rate of mRNA production and thus the rate of 
protein production. A signal leader peptide can be added to the open reading frame of the 
protein of interest which results in translocation of the protein to the periplasmic space where 
chaperones can assist in folding, avoiding the challenges of inclusion bodies and proteases. 
Protein solubility can also be increased by the reduction of temperature after inducing 
expression. Codon optimisation can be used to select for codons commonly found in bacteria 
(as reviewed [216], [218]–[223]). Barth et al. (2000) have proposed a method for the 
production of difficult-to-express proteins in bacteria [224]. To increase the yield of soluble 
recombinant protein, this protocol proposed the use of osmotic stress, which has been reported 
to drive growth rate maximization [224], [225]. Specialised osmotolerant bacteria typically 
combat osmotic environments using organic osmolytes (compatible solutes), which are thought 
to stabilise proteins and organisms under these challenging environmental conditions. This 
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protocol, therefore, made use of osmotic stress in the presence of compatible solutes to produce 
recombinant ITs in E. coli [224], [226].  
HEK293T-cells have been used to produce pseudovirus in vaccine studies, or to express HIV 
epitopes in order to act as HIV infected cells when transfected with recombinant HIV plasmid 
DNA [227], [228]. Plasmids vectors pcDNA-TOPO and pRK have been used for membrane 
surface expression of the HIV Envelope protein on HEK293T-cells to generate pseudoviruses 
for vaccine studies [227], [228]. The complexity of the gp120-gp41 complex is such that other 
expression systems cannot be used. The complex protein folding mechanisms and post-
translational modifications for membrane proteins exclude bacteria and yeast expression 
systems [229], [230]. Other factors that must be taken into consideration when expressing 
membrane proteins include the promoter strength; the transfection reagent, its efficiency, and 
its possible toxicity; as well as the antibiotic resistance genes for positive selection in E. coli. 
The CMV promoter is typically used for mammalian expression as it is a strong constitutive 
promoter [227]–[230].  
 
1.7 Aims of this dissertation 
Having claimed more approximately 37 million lives to date, HIV remains one of the worst 
epidemics in recorded history [4]. The development and initiation of cART have, however, 
resulted in a dramatic decrease in the number of new infections. cART can reduce viremia in 
the blood beyond the limit of detection. A cure has, however, remained elusive due to the 
establishment of viral reservoirs in long-lived memory CD4+ T-cells by HIV. Viral reservoirs 
allow HIV latency in the presence of cART but a swift rebound occurs following the cessation 
of therapy [99], [101]. Strategies to reverse latency have made great strides but are likely to 
fail without cART to prevent new infections, and targeted therapy to eliminate both 
transcriptionally active and latently infected CD4+ T-cells [147]–[150]. Various antibody-
based cancer therapeutics have received approval for human application. ETA-based ITs have 
been used to treat hairy-cell leukaemia [191]. Lessons from cancer therapeutics have therefore 
informed this study. An ETA-based IT targeting HIV-infected Env-expressing CD4+ T-cells 
is a potential therapeutic in the fight against HIV/AIDS. The development of this therapeutic, 
however, must be preceded by the validation of antibody specificity to the antigen. This study, 
therefore, aimed to understand whether (1) a SNAP-tag-based fusion protein, J3-SNAP), can 
be expressed in the periplasmic space of E. coli by osmotic stress in the presence of compatible 
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solutes; and (2) can demonstrate functionality by reacting with readily SNAP-Surface® Alexa 
Fluor® 488 and possibly bind to the cell-surface gp120 of the Env protein. These aims were 
achieved by the following objectives (Figure 1.8 below): (1) in silico design of J3-SNAP, (2) 
molecular cloning to generate the pMT-J3-SNAP recombinant plasmid, (3) osmotic stress 
expression in E. coli BL21 DE3, (4) protein purification by immobilised metal affinity 
chromatography, and (5) confocal microscopy to validate cell surface binding to Env 
expressing cells in vitro. Upon confirmation of preliminary binding of J3 to Env, in silico 




Figure 1.8: Flow chart of the research plan. J3-SNAP was cloned into pMT vector and transformed into E. 
coli BL21 DE3. Protein was expressed under osmotic stress in the presence of compatible solutes. Protein was 
then purified by immobilised metal affinity chromatography (IMAC) and size exclusion chromatography 
(SEC). Purified protein was analysed by SDS-PAGE and Western blot. Protein was then conjugated to SNAP-






Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 Chemicals and consumables 
Unless otherwise stated, chemical reagents were acquired from Sigma-Aldrich (Germany). 
Luria Broth medium and Luria-Bertani agar medium were obtained from Anatech (South 
Africa). Plastic consumables were obtained from Bio-Smart Scientific (South Africa) and 
Lasec (South Africa). 
2.1.2 Buffers and medium 
Buffer solutions and media were prepared according to laboratory protocols using deionised or 
MilliQ water, as appropriate. Aqueous NaOH or HCl was used to adjust the pH of buffer 
solutions. Where necessary, sterile filtration (0.45 µm filter) or autoclaving for 20 minutes at 
121 °C was used to sterilise the solutions. Buffers for IMAC protein purification were filtered 
and de-gassed using a 0.45 µm polyvinylidene difluoride (PVDF) membrane. In cases where 
the medium was supplemented with antibiotics, the following final concentrations were used: 
kanamycin 50 µg/mL, ampicillin 100 µg/mL, penicillin 100 U/mL, streptomycin 100 µg/mL, 
zeocin 100 µg/mL.  
2.1.2.1 Buffers 
Buffer Composition Concentration 
10x Tris-acetate-EDTA (TAE) 
buffer 
Tris base 





















1x TBS-Tween 10x TBS 
dH2O 
Tween 20 
10 % (v/v) 
90 % (v/v) 
0.1 % (v/v) 






1x Transfer buffer  10x Transfer Buffer 
Methanol 
dH2O 
10 % (v/v) 
20 % (v/v) 
70 % (v/v) 








Equilibration buffer for IMAC NaH2PO4NaCl 50 mM 
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pH 8 300 mM 














Lysis solution 2 NaOH 
SDS 
0.2 M 
1 % (w/v) 
Lysis solution 3 Potassium acetate pH 6 3 M 
RIPA (Radio Immuno-
Precipitation Assay) buffer 









1 tab./50 mL 
Lysis buffer Tris-HCl pH 8.0 
NaCl  
DTT 





1 tab./50 mL 
10 % (v/v) 
 
2.1.2.2 Medium 
Medium Composition Concentration 
RPMI complex medium RPMI 1640 plus GlutaMax 




10 % (v/v) 
100 U/mL 
100 µg/mL 














Target Antibody Characteristic 
HIV Envelope (primary) Primary: Sheep anti-gp120 (ARP # 288) Monoclonal 
HIV Envelope 
(secondary) 
Horseradish peroxidase-Goat anti-sheep 
IgG (Santa Cruz 2473) 
conjugated to HRP 
6x Histidine tag 
(primary) 
Rabbit anti-his tag antibody (Cell 
Signalling Technologies, USA) 
Monoclonal 
6x Histidine tag 
(secondary) 
Goat anti-rabbit horseradish peroxidase-
conjugate antibody (Cat: 170-6515, 
Bio-rad Laboratories, USA) 
Conjugated to HRP 
β-actin (primary) Mouse anti-actin (Sigma A2228) Monoclonal 
β-actin (secondary) Horseradish peroxidase-goat-anti-
mouse IgG (R&D HAF007) 




2.1.4 Enzymes and reaction kits 
Kit Purpose Company 
QIAqucik Gel Extraction Kit DNA extraction from 
agarose gels 
Qiagen (USA) 
Zippy Plasmid Miniprep Kit Plasmid DNA isolation Zymo Research (USA) 
 
2.1.5 Synthetic oligonucleotides 
Name Sequence Tm [°C] 
J3-F1 5’ – TGAAGCTTATGGCCCAGCCGGCC – 3’ 60 
J3-R1 5’ – AGCGAGCTCTGCGGCCGCAGAGGAAAC – 3’ 60 
J3-F2 Forward 5’ – ATGGCCCAGCCGGCCGAAGTT – 3’ 60 
J3-R2 Reverse 5’ – GAGTGCGGCCGCAGAGGAAAC – 3’ 60 
SNAP-F1 5’ – GCCGCACTCGAGTCCAGAATGGAC – 3’ 60 
SNAP-R1 5’ – TTATTGCTCAGCGCCAAGACC – 3’ 60 




E. coli DH5α fhuA2 Δ(argF-lacZ)U169 phoA 
glnV44 Φ80Δ (lacZ)M15 gyrA96 
recA1 relA1 endA1 thi-1 hsdR17 
New England Biolabs 
E. coli BL21 (DE3) fhuA2 [lon] ompT gal (λ DE3) 
[dcm] ∆hsdS 
λ DE3 = λ sBamHIo ∆EcoRI-B 
int::(lacI::PlacUV5::T7 gene1) i21 
∆nin5 
New England Biolabs 
HEK293T CRL-11268 ATCC 
 
2.1.7 Plasmid vectors 
Vector system Purpose 
pMT-J3-SNAP Bacterial expression 
pMT-J3-ETA Bacterial expression 





2.2.1 Production and Preparation on DNA 
2.2.1.1 In silico design of recombinant fusion proteins 
The gene sequence of J3 (VHH) was obtained from patent no. WO 2013/036130 A1 and was 
thereafter, aligned to the germline sequence using the IMGT V-QUEST tool 
(www.imgt.org/imgt_vquest) to analyse the FR and CDR regions, and validated by IgBLAST 
(https://www.ncbi.nlm.nih.gov/igblast/). Following this, restriction endonuclease sites for SfiI 
and NotI were added to either side of the J3 (VHH). In silico cloning was performed using 
SnapGene® software (v.5.0.8, GSL Biotech LLC, USA), where the sequence for J3 was 
inserted into appropriate expression plasmid vectors. J3 (VHH) and the plasmid vectors pMT-
H22-ETA and pMT-H22-SNAP were digested using SfiI and NotI. J3 (VHH) substituted H22 
in the pMT-H22-ETA and pMT-H22-SNAP plasmids, to create pMT-J3-ETA and pMT-J3-
SNAP. The ExPASy Translate tool (https://web.expasy.org/translate/) and the ExPASy 
compute pI/MW tool (https://web.expasy.org/cgi-bin/compute_pi/pi_tool) were used to 
determine the theoretical molecular weight (MW) and isoelectric point (pI) of J3-SNAP and 
J3-ETA.  
2.2.1.2 Extraction of plasmid DNA from E. coli 
pMT-H22-ETA and pMT-H22-SNAP plasmid DNA to be used for molecular cloning was 
isolated from E. coli DH5-α donated by Alex Akinrinmade (University of Cape Town, Faculty 
of Health Sciences). Glycerol stocks of E. coli DH5-α were inoculated into 50 mL Luria Broth 
supplemented with kanamycin (200 ng/µL) before being incubated overnight at 37 °C in a 
shaking incubator. Plasmid isolation was performed by alkaline lysis as described by Feliciello 
et al. (1993) [231] with a few modifications. Bacterial cells were then pelleted by centrifugation 
at 3000 rcf (relative centrifugal force) for 10 minutes at 4 °C. The supernatant was discarded, 
and the pellet was then resuspended using lysis solution 1. Cells were lysed and the DNA was 
denatured with lysis solution 2. The mixture was placed on ice for 5 minutes, then, circular 
DNA was renatured with lysis solution 3. Cell debris, denatured DNA, and SDS were then 
removed from the mixture by centrifugation at 13 000 rcf for 10 minutes. To the plasmid DNA-
containing supernatant, RNase-A was added, and the mixture was incubated at 37 °C for one 
hour. Circular plasmid DNA was then precipitated by the addition of 30 % (v/v) isopropanol 
and then incubated at room temperature for 10 minutes. Plasmid DNA was then pelleted by 
centrifugation at 13 000 rcf for 20 minutes, then rinsed with cold 70 % ethanol and dried by 
vacuum centrifugation before being resuspended in nuclease-free water. 
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2.2.1.3 Polymerase chain reaction (PCR) 
The gene fragment for J3, following commercial synthesis by Integrated DNA Technologies 
(USA), was amplified using the oligonucleotides in Table 2.1.5 (J3-F1 and J3-R1) and Phusion 
DNA polymerase (NEB) according to the manufacturer’s instructions. The polymerase chain 
reaction was set up according to Table 2.2.1 below. The components were mixed gently, and 
the reaction was carried out in a thermocycler according to reaction conditions in Table 2.2.2. 
Amplified DNA was visualised by agarose gel electrophoresis. Following electrophoresis, J3 
DNA was excised from the gel using the QIAquick Gel Extraction Kit (Qiagen) according to 
the manufacturer’s instructions. The same protocol was used for mutation by overlap extension 
PCR (OE-PCR). For OE-PCR, the primers J3-F2 and J3-R2 were used to amplify J3. 
Thereafter, SNAP-tag was amplified with the primers SNAP-F1 and SNAP-R1 according to 
Table 2.2.1. J3 and SNAP-tag amplicons were electrophoresed as described in Chapter 2.2.1.5. 
The two amplicons were subsequently sewed together using the primers J3-F2 and SNAP-R1 
according to table 2.2.1 before being electrophoresed as described in Chapter 2.2.1.5. 
Table 2.2.1 Polymerase chain reaction composition using Phusion DNA polymerase. 
Component Concentration 
5x Phusion HF Buffer 1x 
10 mM dNTPs 0.2 mM 
10 µM Forward Primer 0.5 µM 
10 µM Forward Primer 0.5 µM 
J3 gene fragment 0.1 µg 
Phusion DNA polymerase 1000 U/mL 
Nuclease-free H20 13.3 µL 
Total volume 20 µL 
 
Table 2.2.2 PCR amplification thermocycler conditions. 





Denaturation 35 98 10 seconds 
Annealing 60 30 seconds 
Extension 72 30 seconds 
Final Extension 1 72 5 minutes 




2.2.1.4 Restriction endonuclease digestion of DNA 
All restriction enzymes were supplied by NEB and the restriction endonuclease digests were 
carried out according to NEB’s specifications. Here, plasmid DNA (pMT-H22-SNAP and 
pMT-H22-ETA) and J3 or J3-SNAP were digested using restriction endonucleases SfiI (3 hours 
at 50 °C) and NotI-HF (3 hours at 37 °C). Reactions were set up as according to Table 2.2.3 
below.  
Table 2.2.3 Restriction endonuclease digest reaction components 
Component Concentration 
SfiI  1000 U/mL 
NotI 1000 U/mL 
10x NEB Cutsmart Buffer 1x 
DNA 2 µg 
Nuclease-free H2O Adjusted to final volume 
Final volume 20 µL 
 
2.2.1.5 Agarose gel electrophoresis 
DNA fragments were separated by agarose gel electrophoresis using a 1.2 % (w/v) agarose gel 
in 1x TAE buffer supplemented with SYBR safe (1:10 000 dilution) nucleic acid stain 
(Thermo-Fisher Scientific, catalogue number: S33102). As a molecular weight marker, the 
NEB 1 kb and 100 bp marker were used. The gel was electrophoresed at 120 V for 1 hour 
before being visualised under blue light excitation (470 nm). The desired DNA fragments were 
excised from the agarose gel and purified using the QIAquick gel extraction kit according to 
the manufacturer’s instructions. 
2.2.1.6 Ligation of DNA fragments 
Digested, gel-separated, and purified DNA fragments (J3, J3-SNAP, pMT-ETA vector, and 
pMT-SNAP vector) were ligated (J3 + pMT-ETA, J3 + pMT-SNAP, J3-SNAP + pMT) using 
T4 DNA ligase (1000 U/mL) according to Table 2.2.3 below. Ligation reactions were 
performed with plasmid-to-vector ratios 1:3. And 1:5 at 16 °C overnight. The T4 DNA ligase 







Table 2.2.4 T4 DNA ligase reaction conditions 
Component Concentration (1:3) Concentration (1:5) 
10x T4 DNA Ligase buffer 1x 1x 
Vector DNA (7090 bp) 50 ng 50 ng 
Insert DNA (384 bp) [J3] 9 ng 14 ng 
T4 DNA ligase 1000 U/mL 1000 U/mL 
Nuclease-free water Top up to 20 µL Top up to 20 µL 
 
2.2.1.7 Heat shock transformation of competent E. coli 
J3 or J3-SNAP DNA ligated to the plasmid vectors pMT-ETA, pMT-SNAP or pMT (for J3-
SNAP) was transformed into chemically competent E. coli DH5α cells as follows. First, 5 µL 
of the recombinant plasmid (pMT-J3-ETA, pMT-J3-SNAP) was added to 50 µL of competent 
E. coli DH5α cells. The competent cells were incubated on ice for 30 minutes before being 
subjected to heat shock at 42 °C for 1 minute and subsequently incubated on ice for 5 minutes. 
Thereafter, 450 µL of super optimum outgrowth (SOC) medium was added to the mixture 
before being incubated at 37 °C for 60 minutes. The mixture was subsequently centrifuged at 
13 000 rcf for 1 minute. Following this, 300 µL of the supernatant was discarded and the pellet 
was then resuspended in the remaining 200 µL. 100 µL of the remaining mixture was 
inoculated on LB-agar plates supplemented with 50 µg/mL of kanamycin before being 
incubated at 37 °C overnight.  
2.2.1.8 Confirmation of final constructs 
Confirmation if molecular cloning had generated the desired recombinant plasmids (pMT-J3-
ETA and pMT-J3-SNAP) was achieved as follows: several bacterial colonies were selected 
from each plate and grown on LB-agar plates were inoculated into 5 mL Luria broth cultures 
supplemented with 50 µg/mL of kanamycin before incubated at 37 °C overnight. The 
recombinant plasmid was then isolated from 4 mL of the culture using the Zippy plasmid mini 
kit (Zymo Research) as instructed by the manufacturer. SnapGene® software (v.5.0.8, GSL 
Biotech LLC, USA) was used to simulate a restriction endonuclease digest using PvuII to 
generate DNA fragments different from that of the parental plasmid. The recombinant plasmids 
pMT-J3-ETA and pMT-J3-SNAP isolated from E. coli DH5α were thereupon digested using 
PvuII (as with restriction endonuclease digest) at 37 °C overnight. Thereafter, digested DNA 
was analysed by electrophoresis using a 1.2 % agarose gel for 1 hour and before being 
visualised by blue light excitation (470 nm). Once positive clones were identified, the 
remaining 1 mL of the culture was inoculated into 50 mL of Luria broth supplemented with 
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kanamycin and incubated in a shaking incubator at 37 °C overnight. Thereafter, plasmid DNA 
was isolated using the alkaline lysis method (2.2.1.2) and analysed by Sanger sequencing at 
Inqaba Biotech (South Africa). The Sanger sequences were subsequently aligned to the 
consensus sequences to confirm homology and successful molecular cloning of pMT-J3-ETA 
and pMT-J3-SNAP. 
2.2.2 Production of recombinant protein in E. coli 
2.2.2.1 Transformation of competent E. coli 
Confirmed DNA sequences were transformed into the chemically competent expression 
bacterial cell line E. coli BL21 (DE3) according to the previously outlined protocol (2.2.1.7).  
2.2.2.2 Protein stress expression 
Protein expression was carried out using the osmotic stress expression protocol as described 
by Barth et al. (2000) [226]. Briefly, a single E. coli BL21 (DE3) colony containing either 
pMT-J3-ETA or pMT-J3-SNAP was inoculated into 50 mL Terrific Broth (TB) medium 
supplemented with kanamycin and subsequently grown overnight at 28 °C in a shaking 
incubator at 225 rpm. Thereafter, 5 mL of this “Starter culture” was added to 250 mL fresh TB 
media (“main culture”) and incubated at 26 °C at 200 rpm until OD600 = 1.6 is reached. Stress 
was induced by the addition of 4 % NaCl together with 0.5 M sorbitol, 10 mM Glycin-Betain, 
0.5 mM ZnCl2. The mixture was incubated for 30 minutes at 28 °C, after which, IPTG was 
added to a final concentration of 1 mM to induce recombinant protein expression. The culture 
was thereafter incubated at 26 °C for 16 hours. Thereafter, cells were centrifuged at 4000 rcf 
for 10 minutes at 4 °C. 3 supernatant was discarded, and the recombinant protein was harvested 
from the pellet. To harvest the recombinant protein from the bacterial cells, the pellet was 
resuspended in cold lysis buffer before being sonicated to release protein from the periplasmic 
space. The lysate was thereafter centrifuged at 24 000 rcf for 30 minutes. The supernatant was 
clarified using a 0.45 µm syringe filter before being enriched by IMAC. 
2.2.3 Protein purification and analysis 
2.2.3.1 Protein purification by IMAC 
The recombinant fusion protein was enriched by fast protein liquid chromatography (FPLC) 
on an ÄKTA ExplorerTM (GE Healthcare) using a HisTrap™ High Performance column (GE 
Healthcare, 17-5247-01). Using a flow rate of 5 mL/min (maintained throughout the 
purification process), the column was equilibrated with 10 column volumes of equilibration 
buffer. Cell lysate containing recombinant fusion protein was subsequently applied to the 
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column. The column was again washed with 10 column volumes of incubation buffer. Bound 
protein was then eluted with elution buffer using increasing concentrations of imidazole-
containing elution buffer. Initially, 6 % imidazole in elution buffer was used to elute weakly-
bound protein. The protein of interest was then eluted using 40 % imidazole, then 100 % 
imidazole. The eluted protein was concentrated using Amicon® Ultra-15 centrifugal filter units 
(Ref: UFC901008, Sigma) with 10 kDa cut off membranes. Protein fractions were pooled and 
concentrated using a 50 kDa Amicon® Ultra-15 centrifugal filter unit which traps proteins 
greater than 50 kDa. The centrifugation was carried out for 25 minutes at 4 °C at 4000 rcf. The 
flow-through was then applied to a 10 kDa Amicon® Ultra-15 centrifugal filter unit which 
further excluded all proteins below 10 kDa. The sample trapped by the 50 kDa Amicon® Ultra-
15 centrifugal filter unit was kept for analysis. The protein of interest was expected to be below 
50 kDa and above 10 kDa (J3-SNAP – 37.5 kDa). The flow-through that was not trapped by 
the 10 kDa Amicon® Ultra-15 centrifugal filter unit was kept for analysis by SDS-PAGE 
(Chapter 2.2.3.2) and Western blot (Chapter 2.2.3.3). 
2.2.3.2 SDS-polyacrylamide gel electrophoresis 
Enriched protein was separated by discontinuous SDS-PAGE using 10 % (w/v) SDS gels. As 
a protein standard, pre-stained protein marker was used. 15 µL of the fraction was mixed with 
5 µL of 4x Laemmli Sample Buffer (Bio-rad, USA #1610747) before being boiled to denature 
and analysed by SDS-PAGE at 80 V for 30 minutes and then at 120 V for 1 hour. Protein bands 
were subsequently visualised by incubation of the gel in AcquaStain® solution (Bulldog Bio, 
USA) for at least 30 minutes.  
2.2.3.3 Western blot 
Where necessary, following protein separation by SDS-PAGE, the protein was transferred onto 
a nitrocellulose membrane as follows. The membrane was equilibrated for 5 min in methanol, 
followed by incubation for 5 min in water and, lastly, for 5min in transfer buffer. The transfer 
was subsequently carried out at 90 V for 90 minutes using The Mini Trans-Blot® cell (Bio-
rad, USA). The membrane was then blocked with 10 % milk in 1x PBS for 1 hour at room 
temperature. Thereafter, the membrane was washed with 1x PBS-Tween three times for 10 
minutes. The recombinant protein was detected using rabbit monoclonal anti-His-tag (1:1000, 
Qiagen Germany) and Goat anti-rabbit horseradish peroxidase-conjugate antibody (1: 5000) 
(Bio-rad, USA). For detection of β-actin, the membrane was then incubated with Mouse anti-
actin antibody (Sigma A2228) for an hour at room temperature, and then Horseradish 
peroxidase-goat-anti-mouse IgG (R&D HAF007) for one hour at room temperature before 
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being viewed by Gel Doc Protein was then quantified using the Denovix DS-11 
spectrophotometer (Alliance Global, USA).  
2.2.4 Evaluation of protein functionality 
2.2.4.1 Cell culture of HIV Env-expressing HEK293T-cell line 
Human embryonic kidney 293T (HEK293T) cells were used for the generation of a cell line 
expressing cell-surface recombinant Env glycoprotein. To generate the Env-expressing cells, 
glycerol stocks of E. coli containing the plasmid pcDNA-TOPO-gp120, which encodes 
recombinant full-length Env protein (gp120 and gp41) were kindly donated by Dr. Zenda 
Woodman (University of Cape Town, South Africa). Plasmid DNA was isolated by the alkaline 
lysis method (as described in Chapter 2.2.1.2) before being transiently transfected into the 
HEK293T-cells. For transient transfection, 3 x 105 HEK293T-cells in supplemented RPMI-
1640 cell culture medium, were seeded per well in a 6-well plate before being incubated at 37 
°C overnight with 5 % CO2. Thereafter, 3 µg of pcDNA-TOPO-gp120 plasmid was mixed with 
9 µL polyethyleneimine (PEI) (1 mg/mL) in 400 µL of the supplement-free medium. The 
mixture was vortexed for 15 seconds before being incubated at room temperature for 20 
minutes. Before the addition of the DNA-PEI complex, 1.5 mL fresh medium was added to 
each well and the complex was added gently in a dropwise manner. The HEK293T-cells were 
incubated at 37 °C with 5 % CO2 for 6 hours. The medium was changed thereafter, and the 
cells were incubated for a further 48 hours. The cells were subsequently washed gently with 1x 
PBS twice before being incubated with 500 µL cold RIPA (Table 2.1.2) buffer on ice for 5 
minutes. The cells were then resuspended, and the lysate was transferred to a microcentrifuge 
tube before being centrifuged at 13 000 rcf for 5 minutes. The protein was separated by SDS-
PAGE and transferred onto nitrocellulose membrane where gp120 was detected using sheep 
anti-gp120 (ARP #288) and horseradish peroxidase goat-anti-sheep IgG (Santa Cruz 2473). As 
a positive control, HIV-1 IIIB gp120 Recombinant Protein (Cat # 11784) was used, having 
been obtained from the NIH AIDS reagent program (https://www.aidsreagent.org/). 
2.2.4.2 Cell-surface binding study by confocal microscopy 
To assess cell-surface binding of the enriched SNAP fusion protein on Env protein-expressing 
HEK293T-cells, the protein J3-SNAP (5 µM) was conjugated to the SNAP-Surface® Alexa 
Fluor® 488 (10 µM) to achieve a protein to fluorophore molar ratio of 1:2, in the presence of 
1 mM DTT, and incubated for 30 minutes 37 °C in the dark. Thereafter, 3 x 105 Env protein-
expressing HEK293T-cells were seeded in supplemented RPMI-1640 medium in a 4-
chambered 30 mm dish and allowed to settle overnight. The cells were washed with 1x PBS 
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twice before being incubated with 2 µg of protein in 100 µL of 1x PBS for 30 minutes on ice. 
Unbound protein was washed off. The cells were then stained with Hoechst 33342 (1 µg/mL) 
in supplemented-free media for 10 minutes. The cells were washed with 1x PBS before being 
viewed using a Zeiss LSM 880 confocal microscope operated using ZEN software (Zeiss, 
South Africa). 
2.2.5 Development of J3-ETA 
Following the expression of J3-SNAP in bacteria and the conformation of functional activity 
by successful binding to Env protein-expressing HEK293T-cells, J3-ETA was developed as 




Chapter 3: Results 
3.1 Development of J3-SNAP 
Advances in medicine in general and antiretroviral therapy, in particular, have resulted in the 
development of cART capable of reducing viremia to undetectable levels (< 40 copies/mL) 
[103]. The initiation of cART has been shown to allow the restoration of immune competence 
[232], [233]. To prevent a relapse of viremia, however, lifelong cART must be maintained. 
This brings about increased likelihood of off-target toxicity and drug-drug interactions related 
to antiretroviral therapy [234]–[236]. Curative strategies are being investigated to combat the 
HIV/AIDS epidemic, which has claimed more than 38 million lives, but no cure has been found 
to date. Cardinal strides in the quest for an HIV vaccine have been made through the discovery 
of neutralizing antibodies capable of specific binding to the HIV Env protein expressed in 
various HIV subtypes [208]. One study tested isolated VHH nanobodies from immunised 
llamas for binding against one hundred HIV strains and found that one antibody (J3) was able 
to neutralise more than 95 % of the tested strains. Therefore, the major aim of this study was 
to determine whether functional J3-SNAP fusion protein could be expressed in E. coli BL21 
DE3. Upon confirmation of functionality by cell-surface binding to Env protein-expressing 
cells, in silico design and molecular cloning of J3-ETA was commenced. 
3.1.1 pMT-J3-SNAP in silico cloning 
The in silico cloning began with the analysis of the plasmid vector pMT-H22-SNAP and pMT-
H22-ETA. This was carried out to identify the appropriate restriction endonuclease sites for 
the introduction of the gene of interest. To realise the cloning of J3-SNAP and J3-ETA (as 
described in Chapter 2.2.1), a single-domain heavy-chain nanobody (VHH) sequence (J3) 
targeting HIV was obtained from patent no. WO 2013/036130 AI. To analyse the sequence of 
J3, validate the V gene, and identify the FR and CDR regions, the sequence was aligned to the 
human germline sequence IgHV3 using the IMGT V-QUEST tool  
(www.imgt.org/imgt_vquest) and validated by IgBLAST 
(https://www.ncbi.nlm.nih.gov/igblast/). J3 was validated to be a VH chain and shared a 64.87 
% sequence identity to the human germline sequence. J3 exhibited a shorter CDR2 region when 
compared to the germline sequence and the variation from the germline sequence are 
represented in bold text (Figure 3.1A). J3 gene was modified to introduce restriction 
endonuclease cleavage sites to allow for incorporation into a suitable protein expression vector. 
SnapGene® software (v.5.0.8, GSL Biotech LLC, USA) was used for the in silico cloning of 
J3, where a simulation of J3 restriction endonuclease digest of J3 and subsequent ligation to a 
47 
 
suitable bacterial expression vector was performed. J3 was ligated to the pMT bacterial 
expression plasmid in silico as described in Figure 3.1 B. The resulting plasmids were 
designated pMT-J3-SNAP and pMT-J3-ETA (Figure 3.1 C-D). The MW and pI of J3-SNAP 
was estimated using the ExPASy translate tool (https://web.expasy.org/translate/) and the 
ExPASy compute pI/MW tool (https://web.expasy.org/cgi-bin/compute_pi/pi_tooland 
theorised to be approximately 37.55 kDa and 6.59 respectively. J3 was thereafter commercially 










Figure 3.1: In silico design of the expression plasmids for pMT-J3-SNAP and pMT-J3-ETA. A) The 
amino acid sequence of J3 obtained from patent no. WO 2013/036130 AI, analysed by IMGT V-QUEST tool 
(www.imgt.org/imgt_vquest), aligned with a human germline sequence. FR and CDR regions identified. B) Open 
reading frame (ORF) of J3 (VHH) digested using restriction endonucleases SfiI and NotI replacing H22 
digested with the same restriction endonucleases to create J3-ETA and J3-SNAP. C) Plasmid vector map of 
pMT-J3-ETA containing the J3 (VHH) gene and pseudomonas exotoxin A (ETA). D) Plasmid vector map of 
pMT-J3-SNAP containing the J3 (VHH) gene and SNAP-tag. Both C and D plasmid vectors also contain the 
following genes; F1 bacteriophage origin of replication; kanamycin/neomycin resistance gene; the origin of 
replication; the basis of mobility region pBR322, which confers plasmid conjugation; Rop gene, which 
maintains plasmid at high copy number; LacI, the lac repressor gene bind to the lac operator and inhibits 
transcription in E. coli until the addition of isopropyl β- d-1-thiogalactopyranoside (IPTG); lacI promoter 
region; T7 promoter region for T7 bacteriophage RNA polymerase; RBS, ribosome binding site for RNA 
polymerase; pelB signal sequence, signals that protein should be translocated to the periplasmic space of 
bacteria; 10x histidine affinity tag; EKS, enterokinase recognition and cleavage site; J3 (VHH) gene; 
ETA or SNAP-tag gene; T7 terminator, transcription termination site for T7 bacteriophage RNA 
polymerase. (open reading frame in bold text) [as described in Chapter 2.2.1.1] 
 
3.1.2 Development of pMT-J3-SNAP 
The synthesised gene fragment of J3 was amplified by PCR using Phusion DNA polymerase 
(1000 U/mL) [Table 2.2.1]. The PCR amplicon was analysed by agarose gel electrophoresis. 
The PCR amplicon of J3 (Figure 3.2 A) was visualised at the expected size of approximately 
380 bp. J3 was thereafter excised from the agarose gel and purified before being digested by 
SfiI and NotI restriction endonucleases. The restriction endonuclease digested J3 was further 
analysed by agarose gel electrophoresis and visualised at approximately 380 bp before being 
again excised from the agarose gel and purified (as detailed Chapter 2.2.1.5).  
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To generate pMT-J3-SNAP, 3 µg of sequence-validated pMT-H22-SNAP plasmid was 
digested with SfiI + NotI restriction endonucleases to replace H22 (scFv) by J3 [Table 2.2.3]. 
50 µL of restriction endonuclease-digested pMT-H22-SNAP was subsequently mixed with 1:6 
dilution of Gel Loading Dye, Purple (6X) [NEB - #B7024S] and analysed by agarose gel (1.2 
% v/v) electrophoresis at 120 V for 1 hour (as described in Chapter 2.2.1.5). Successful 
restriction endonuclease digestion was confirmed by the presence of two distinct bands at 
approximately 800 bp (H22) (Figure 3.2 B) and 6 kb (pMT-SNAP) for the SfiI + NotI digests. 
Restriction endonuclease digests were run in triplicate. Undigested pMT-H22-SNAP was used 





Figure 3.2: Construction of pMT-J3-SNAP by polymerase chain reaction amplification of J3 and 
endonuclease digest of J3 and pMT-H22-SNAP. A) 1 ng of J3 was amplified by PCR. 20 µL of PCR product 
was mixed with Gel Loading Dye, Purple (6X) [NEB - #B7024S] (1:6 dilution) and analysed by agarose gel 
electrophoresis. J3 was then excised and purified from agarose gel. J3 (A) and 3 µg of pMT-H22-SNAP (B) 
were digested using 1000 U/mL SfiI and NotI restriction endonucleases for 3 hours at 50 °C and overnight at 37 
°C respectively. 50 µL of digest product was mixed with 1:6 dilution of Gel Loading Dye, Purple (6X) [NEB - 
#B7024S] immediately before being loaded onto an agarose gel. Gels A and B were 1.2 % agarose gels run at 
120 V for 1 hour before being viewed under blue light excitation (470 nm). UD – undigested control. NotI/SfiI 
- single-enzyme digest control. DD, double enzyme digest. MW – molecular weight marker (as detailed in 
Chapter 2.2.1). 
  
The insert, J3, and the plasmid vector, pMT-SNAP, were ligated using their 5’-phosphorylated 
and 3’-hydroxylated compatible ends generated through SfiI + NotI restriction endonuclease 
digestion. For this reaction, 9 ng and 14 ng of J3 was ligated to using T4 DNA ligase 50 ng of 
pMT-SNAP in a 3:1 and 5:1 insert-to-vector molar ratio, respectively (Table 2.2.4). The 
ligation reaction product, pMT-J3-SNAP, was transformed into chemically competent DH5α 
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E. coli cells before being grown on LB-agar plates supplemented with kanamycin (50 µg/mL) 
overnight at 37 °C. A vector + ligase control was included as a negative control that lacks the 
insert J3 and hence has linearized plasmid. Nevertheless, we observed a colony-forming units 
(CFU) value of 0.61 x 104 in the negative control (Figure 3.3 A). The CFU for the 3:1 (Figure 














Figure 3.3: DH5α E. coli cells transformed with pMT-J3-SNAP grown on LB-Agar plates supplemented 
with kanamycin. Recombinant pMT-J3-SNAP plasmids generated through ligation of J3 to pMT-SNAP with 
an insert to vector ratio of 3:1 and 5:1 for each were transformed in DH5α E. coli cells as described and were 
subsequently grown on kanamycin-supplemented (50 µg/mL) LB-Agar plates for 16 hours at 37 °C. 
Kanamycin was used as selection pressure, allowing only cells that have taken up ligated circular recombinant 




To verify the identity of the plasmids contained within the bacterial clones in Figure 3.3 B and 
C, four colonies were selected at random from each plate and inoculated into 5 mL LB-broth 
media supplemented with 50 µg/mL of kanamycin. The inoculated 5 mL cultures were 
incubated to grow overnight at 37 °C, after which, 4 mL of the 5 mL was used for miniprep 
plasmid isolation. The isolated plasmid (pMT-J3-SNAP) was subsequently used for restriction 
endonuclease mapping using PvuII. pMT-H22-SNAP was used as a control. 100 µg of the 
plasmid (pMT-J3-SNAP and pMT-H22-SNAP) was digested using 1000 U/mL of PvuII at 37 
°C for 2 hours before being analysed by agarose gel electrophoresis (Table 2.2.3). SnapGene® 
software (v.5.0.8, GSL Biotech LLC, USA) was used to simulate an agarose gel depicting the 
DNA fragments resulting from the PvuII restriction endonuclease digest of either pMT-H22-
SNAP or pMT-J3-SNAP (Figure 3.4 A). The simulation predicted that pMT-H22-SNAP 
digested using PvuII resulted in three fragments of sizes 3724 bp, 1599 bp, and 999 bp. The 
simulation predicted that pMT-J3-SNAP digested using PvuII resulted in two fragments of 
sizes 5344 bp and 999 bp. Consistently, the agarose gel (Figure 3.4 B) depicted that pMT-H22-
SNAP digested using PvuII resulted in three bands at the approximate size of the simulated 
gel. Although all four of the 3:1 and three of the 5:1 insert-to-vector ratio colonies corresponded 
to the SnapGene® simulation, one of the 5:1 ratio colonies (Figure 3.3 C) appeared similar to 
the pMT-H22-SNAP control instead of pMT-J3-SNAP (Figure 3.4 B – lane 8). Furthermore, 
rather than a 999 bp band in the 3:1 and 5:1 colonies, a 1599 bp band was observed. 
Nevertheless, the clones that appeared as expected were inoculated into 50 mL LB-broth 
cultures supplemented with 50 µg/mL of kanamycin overnight at 37 °C. Thereafter, the 
recombinant pMT-J3-SNAP plasmid was isolated by alkaline lysis method (as detailed in 
Chapter 2.2.1.2) and analysed by Sanger sequencing (Figure 3.4 D). Subsequent sequence 
alignment of Sanger sequences to the consensus sequence confirmed that the selected clones 
did indeed contain pMT-J3-SNAP. The Sanger sequencing also highlighted a mutation in the 
form of a deletion of a base pair. A nucleotide was missing between J3 and SNAP, resulting in 














Figure 3.4: pMT-J3-SNAP Sequence confirmation by restriction endonuclease mapping of the 
recombinant plasmid. A) SnapGene® software (v.5.0.8, GSL Biotech LLC, USA) was used to simulate an 
agarose gel of pMT-H22-SNAP and pMT-J3-SNAP digested using PvuII. B) 3 µg pMT-H22-SNAP, pMT-J3-
SNAP was digested using 1000 U/mL of restriction endonuclease PvuII at 37 °C overnight. 50 µL of restriction 
endonuclease digest product was mixed with a 1:6 dilution of Gel Loading Dye, Purple (6X) [NEB - #B7024S] 
and run on 1.2 % agarose gel at 120 V for 1 hour before being visualised under blue light excitation (470 nm). 







3.1.3 Nucleotide base insertion by overlap-extension PCR 
 
Figure 3.5: Illustration of point mutation by overlap-extension PCR. Primers J3-F2 and J3-R2 are used to 
amplify J3 in one reaction tube. Primers SNAP-F1 and SNAP-R1 and used to amplify SNAP-tag in a separate 
reaction tube. Primers J3-F2 and SNAP-R1 and used to join the J3 amplicon and the SNAP-tag amplicon. 
Primers J3-R2 and SNAP-F1 overlap over the site of the point mutation, binding to separate strands (Table 
2.2.1). 
To insert the missing nucleotide, overlap-extension PCR was used as illustrated in Figure 3.5. 
Four primers (Table 2.1.5) were designed to amplify J3 and SNAP individually from the 
mutated pMT-J3-SNAP plasmid vector. Two external primers were designed to bind to the 
different strands of DNA:  a J3 forward primer (J3-F2) and a reverse primer for SNAP (SNAP-
R1). Two internal primers were designed, which overlap with one another overlapping at the 
mutated region and binding to different strands: a reverse primer for J3 (J3-R2) and a forward 
primer for SNAP (SNAP-F1). J3 and SNAP were amplified separately by PCR (Table 2.2.1). 
PCR product was thereafter analysed by agarose gel electrophoresis (as described in Chapter 
2.2.1.5). The individually amplified J3 and SNAP were excised from the agarose gel and 
purified before being joined together using the J3 forward primer and SNAP reverse primer in 
a second PCR step. PCR-amplified DNA was separated by agarose gel electrophoresis and the 
band corresponding to J3-SNAP was excised from the agarose gel and purified. Subsequently, 
the purified J3-SNAP DNA was digested using SfiI and BlpI restriction endonucleases (Table 
2.2.3), and the digest products were separated by agarose gel electrophoresis (Figure 3.6 D). 
Thereafter, J3-SNAP (SfiI-BlpI) was excised from the agarose gel and purified. Concurrently, 
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the mutated pMT-J3-SNAP plasmid was digested using SfiI + BlpI to remove the mutated J3-
SNAP from the plasmid vector. Mutated pMT-J3-SNAP digested by SfiI + BlpI was 
subsequently analysed by agarose gel electrophoresis. SnapGene® software (v.5.0.8, GSL 
Biotech LLC, USA) was used to simulate PCR amplicons of J3, SNAP, and J3-SNAP, as well 
as a restriction endonuclease digest of mutated pMT-J3-SNAP plasmid vector (Figure 3.6 A). 
The SnapGene® simulation predicted that J3 amplified would result in a 390 bp fragment 
(Figure 3.6 A – lane 2). This correlated with the agarose gel. A band was seen at approximately 
400 bp (Figure 3.6 B – lanes 2-5). Accordingly, the SnapGene® simulation predicted that the 
amplified SNAP would be at 576 bp (Figure 3.6 A – lane 3), and on the agarose gel, a band 
was seen at approximately 600 bp (Figure 3.6 B – lanes 6-10). PCR-amplified J3-SNAP was 
visualised at approximately 900 bp (Figure 3.6 C), which corresponded to the simulated 
amplicon of 957 bp (Figure 3.6 A -lane 3). Mutated pMT-J3-SNAP digested with SfiI and BlpI 
was expected to have two fragments, at 5499 bp, and at 930 bp, which corresponded with the 
experimental result (Figure 3.6 E). The PCR-generated J3-SNAP and the pMT plasmid vector 













Figure 3.6: Nucleotide insertion by overlap extension PCR. J3 and SNAP were amplified individually by 
PCR using two external primers and two overlapping internal primers, then amplified using the external primers 
to make J3-SNAP. A) SnapGene® software (v.5.0.8, GSL Biotech LLC, USA) was used to simulate an agarose 
gel depicting PCR-amplified J3 (lane 2), SNAP (lane 3), J3-SNAP (lane 4), and SfiI + BlpI digested pMT-J3-
SNAP (lane 5). B) J3-specific and SNAP-specific primers were used to amplify J3 and SNAP from pMT-J3-
SNAP. C) J3 and SNAP were fused using external primers. D) J3-SNAP was digested using SfiI + BlpI at 50 
°C for 3 hours and 37 °C overnight respectively. E) pMT-J3-SNAP was digested using SfiI + BlpI at 50 °C for 
3 hours and 37 °C overnight respectively. UD - undigested, SfiI, and BlpI single enzyme digested controls were 
included. 50 µL of PCR and digest products were mixed with a 1:6 dilution Gel Loading Dye, Purple (6X) 
[NEB - #B7024S] and analysed using a 1.2 % agarose gel at 120 V for 1 hour before being viewed under blue 
light excitation (470 nm) (as detailed in Chapter 2.2.1). F) Alignment of J3-SNAP Sanger sequences to the 
consensus sequence (as detailed in Chapter 2.2.1.8). 
 
T4 DNA ligase (1000 U/mL) was used to ligate the J3-SNAP insert into the pMT plasmid 
vector in a 3:1 (24 ng – 50 ng), and a 5:1 (42 ng – 50 ng) insert to vector molar ratio. A vector 
+ ligase control comprised of the linearized vector without the insert was included. The ligation 
product was transformed into DH5α E. coli cells before being inoculated on LB-agar plates 
supplemented with 50 µg/mL kanamycin and incubated overnight at 37 °C. Colonies were 
selected from the 3:1 and the 5:1 LB-agar plates at random and inoculated into 5 mL LB-broth 
medium supplemented with 50 µg/mL of kanamycin and incubated at 37 °C overnight. The 
pMT-J3-SNAP plasmid was isolated from the cultures by miniprep plasmid isolation before 
being analysed by Sanger sequencing. Multiple sequence alignment of the Sanger sequences 
to the consensus sequence (Figure 3.6 F) showed thatJ3-SNAP had been successfully inserted 
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into the pMT plasmid vector without any nucleotides missing. For protein expression, pMT-
J3-SNAP DNA confirmed by Sanger sequencing was transformed into E. coli BL21 DE3 cells, 
which were inoculated onto LB-agar plates supplemented with kanamycin (50 µg/mL). The 
CFU/mL values were 0.34 x 104 and 1.5 x 105 for the untransformed control plate and test plate 
respectively.  
A B 
Bacteria only control pMT-J3-SNAP 
  
Figure 3.7: LB-agar plates with BL21 DE3 E. coli cells transformed with pMT-J3-SNAP. 1200 ng of 
recombinant plasmid pMT-J3-SNAP was transformed into E. coli Bl21 DE3 cells. Transformed cells were 
inoculated on LB-agar plates supplemented with 50 µg/mL of kanamycin. Plates were incubated at 37 °C for 
16 hours (as detailed in Chapter 2.2.2.1).  
 
3.1.3 Osmotic-stress expression in the presence of compatible solutes 
As described in Chapter 2.2.2, a single colony was inoculated into a 50 mL culture of TB media 
supplemented with 50 µg/mL of kanamycin before being incubated at 28 °C overnight. 40 mL 
of this “starter culture” was inoculated into 2.8 L of TB “main culture” supplemented with 50 
µg/mL of kanamycin before being incubated at 26 °C. Osmotic stress was induced by adding 
4 % NaCl in the presence of compatible solutes (0.5M sorbitol, 40 mM glycine-betaine, 0.5 
mM ZnCl) when the OD600 value reached 1.6. After 30 minutes, 1 M IPTG was added to 
induced periplasmic expression. The culture was allowed to grow for 16 hours at 26 °C. The 
bacterial cells were centrifuged at 4000 rcf for 10 minutes at 4 °C before being resuspended in 
cell lysis buffer (75 mM Tris HCl, 300 mM NaCl, 5 mM DTT, protease inhibitor cocktail, 10 
% v/v glycerol). The protein was extracted from the periplasmic space by sonication for 2 
minutes. The bacterial lysate was subsequently centrifuged at 24 000 rcf for 30 minutes at 4 
°C. The supernatant was filtered using a 0.45 µM syringe filter before being applied onto a 
HisTrap™ High Performance column (GE Healthcare, 17-5247-01). Protein interaction with 
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the column was facilitated by the 10x histidine tags located on the N-terminus of J3-SNAP. 
Imidazole was used to elute the protein from the column through competitive binding (Buffers 
– Chapter 2.1.2). Eluted fractions were collected and analysed by SDS-PAGE, where 15 µL of 
each fraction of eluted protein was mixed with 5 µL 4x Laemmli Sample Buffer (Bio-rad, USA 
#1610747) and resolved on a 7.5 % acrylamide gel. SDS-PAGE allowed separation of protein, 
based on molecular weight and thus visualization of the protein of interest. SDS-PAGE was 
performed at 80 V for 30 minutes, then 120 V for 1 hour. The acrylamide gel was then stained 
with AcquaStain® protein gel stain for no less than 30 minutes before being visualised (Figure 
3.8 A-B). In Figure 3.8 A, multiple protein bands were observed from lanes 1 - 9, corresponding 
to the order in which the fractions were eluted from the HisTrap™ High Performance column 
(GE Healthcare, 17-5247-01). Distinct and consistent protein bands were observed at 
approximately 72 kDa and 70 kDa, at 46 kDa, 34 kDa, 32 kDa, and at 26 kDa. Figure 3.8 B 
shows the remaining fractions eluted from the HisTrap™ High Performance column (GE 
Healthcare, 17-5247-01) and were represented in the order in which they were eluted. The 
bands at 72 kDa and 70 kDa persisted, together with the bands at 34 kDa, 32 kDa, and 26 kDa. 
The concentration of the protein appeared to intensify in Figure 3.8 B from lanes 4 - 8, with 
more distinct bands of the protein at approximately 32 kDa (suspected to be J3-SNAP). To 
verify the identity of the protein purified, the protein fractions depicted in Figure 3.8 B were 
pooled and concentrated using a 50 kDa column. To select for and concentrate the protein of 
interest, protein concentration was performed using a 50 kDa and a 10 kDa Amicon® Ultra-15 
centrifugal filter unit. Fractions from Figure B 1 - 9 were pooled applied to a 50 kDa Amicon® 
Ultra-15 centrifugal filter unit and centrifuged at 4000 rcf for 25 minutes at 4 °C. The flow-
through was thereafter concentrated using a 10 kDa Amicon® Ultra-15 centrifugal filter unit 
which further excluded all proteins below 10 kDa. The total concentrated protein was then 
quantified at 280nm using the Denovix DS-11 spectrophotometer (Alliance Global, USA) and 
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Figure 3.8: Purification of J3-SNAP by immobilised-metal affinity chromatography. Following the 
periplasmic expression of J3 in E. coli, fractions of his-tagged protein were analysed by SDS-PAGE using a 
10 % (w/v) acrylamide gel (A & B). 15 µL of the fraction was mixed with 5 µL of 4x Laemmli Sample Buffer 
(Bio-rad, USA #1610747) before being boiled and analysed by SDS-PAGE. Fraction were eluted at 7 % 
imidazole (A) then 60 % (B). C) cell lysates and fractions [uninduced – 5 µL; induced 5 µL; who-cell lysate 
(WL) – 10 µL; cleared-cell lysate (CL) – 10 µL; wash – 20 µL; >50 kDa fractions – 15 µL, >10 kDa fractions 
– 15 µL; flow-through – 20 µL] were mixed with 5 µL of 4x Laemmli Sample Buffer (Bio-rad, USA #1610747) 
before being analysed by SDS-PAGE at 120 V for 1 hour. Protein was then transferred to nitrocellulose 
membrane at 90 V for 2 hours. Rabbit anti-His tag antibody (Cell Signalling Technologies, USA) and goat 
anti-rabbit horseradish peroxidase-conjugate antibody (Bio-rad Laboratories, USA) were used to detect His-
tag protein. Pierce™ ECL Plus Western blotting Substrate (Thermo Scientific, USA #32134) was used to detect 
chemiluminescence (as described in chapter 2.2.3).  
 
The concentrated protein was analysed by SDS-PAGE and Western blot, together with cell 
lysates including “induced”, “uninduced”, “whole-cell” and “cleared cell” lysate. Rabbit anti-
histidine primary antibody (Cell Signalling Technologies, USA) and goat anti-rabbit 
horseradish peroxidase-conjugate antibody (Bio-rad Laboratories, USA) were used to detect 
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10x histidine in the cell lysates. In Figure 3.8 C, no bands were visible in the “uninduced cell 
lysate” sample. Two faint bands were visible at approximately 34 kDa and 26 kDa in the 
“induced” lysate “whole-cell” lysate, “cleared cell” lysate, “wash”, “50 kDa” fraction, and “10 
kDa” samples. The third band below 26 kDa was observed for the “cleared cell” lysate and 
“wash” samples. 
3.1.4 Generation of Env protein-expressing HEK293T-cells 
To generate an Env protein-expressing cell line on which to evaluate the functionality of J3-
SNAP, plasmid DNA (pcDNA-TOPO-gp120), kindly donated by Dr. Zenda Woodman 
(University of Cape Town, South Africa), encoding recombinant full-length Env protein 
subtype C was transfected using polyethyleneimine (PEI) into HEK293T-cells for cell-surface 
expression. For this experiment (as described in Chapter 2.2.4.1), 3 x 105 HEK293T-cells were 
seeded per well in a 6-well plate before and incubated at 37 °C overnight with 5 % CO2. The 
following day, 3 µg of pcDNA-TOPO-gp120 plasmid was mixed with 9 µL PEI (1 mg/mL) in 
supplement RPMI medium and vortexed for 15 seconds and incubated at room temperature for 
20 minutes. Before the addition of the DNA-PEI complex, 1.5 mL fresh medium was added to 
each well and the complex was added gently in a dropwise manner. The HEK293T-cells were 
incubated at 37 °C with 5 % CO2 for 6 hours. The medium was changed thereafter, and the 
cells were incubated for a further 48 hours. To assess if Env protein had been expressed, the 
cells were washed with 1x PBS, lysed with RIPA buffer (Table 2.1.2), and centrifuged at 
13 000 rcf for 5 minutes. The cellular protein was separated by SDS-PAGE and transferred 
onto a nitrocellulose membrane where gp120 of the Env protein was detected using sheep anti-
gp120 (ARP #288) and horseradish peroxidase goat-anti-sheep IgG (Santa Cruz 2473). Bands 
were observed at approximately 160 kDa and 42 kDa across all samples. The bands at 160 kDa 
were thought to be that of the Env protein (gp120 + gp41 complex), and β-actin was detected 




Figure 3.9: Cell-surface expression of HIV Env protein in HEK293T-cells. Recombinant pcDNA-TOPO-
gp120 (3 µ) plasmid was transfected into HEK293T-cells using PEI (9 µL) (1 mg/mL). After 48 hours, cells 
were lysed using RIPA buffer (Table 2.1.2) and centrifuged at 15 000 rcf for 5 minutes. 20 µL of supernatant 
was mixed with 5 µL of 4x Laemmli Sample Buffer (Bio-rad, USA #1610747) and analysed by SDS-PAGE at 
120 V for 1 hour. Protein was transferred onto a nitrocellulose membrane at 80 V for 2 hours. Sheep anti-gp120 
(ARP # 288) and Horseradish Peroxidase-Goat anti-sheep IgG (Santa Cruz 2473) were used to detect HIV Env. 
Mouse anti-actin and goat anti-mouse IgG were used to detect β-actin. PierceTM ECL Plus Western blotting 
Substrate (Thermo Scientific, USA #32134) was used to detect chemiluminescence. pcDNA without Env DNA 
was used as a negative control. Recombinant gp120 protein was used as a positive control (as described in 
Chapter 2.2.4.1). 
 
3.1.5 Evaluation of the binding of J3-SNAP-Alexa Flour ® 488 to envelope protein localised 
on the surface of HEK293T-cells 
After generating an Env protein-expressing cell line, the cell-surface binding of J3-SNAP 
conjugated to SNAP-Surface® Alexa Fluor® 488, to the surface of Env protein-expressing 
cells was evaluated by confocal microscopy. For this experiment, 3 x 105 Env protein-
expressing HEK293T-cells were seeded per well in a 6-well plate before and incubated at 37 
°C overnight with 5 % CO2. The protein J3-SNAP was conjugated to 10 µM of SNAP-
Surface® Alexa Fluor® 488 in the presence of DTT and incubated at 37 °C for 30 minutes 
(Figure 1.6). Env protein-expressing HEK-293T-cells were incubated with 2 µg of J3-SNAP-
Alexa Flour® 488 for 30 minutes on ice before being visualised by confocal microscopy. A 
green signal was observed on the surface of the HEK293T-cells (Figure 3.10 A). The cell 






















SNAP-Surface® Alexa Fluor® 488 + Hoechst 33342 Bright light image  
Figure 3.10 Confocal microscopy depicting SNAP-Surface® Alexa Fluor® 488-labelled J3-SNAP 
targeting gp120 on HEK293T-cells. To label the SNAP-fusion protein, 5 µM of J3-SNAP was conjugated to 
62 
 
SNAP-Surface® Alexa Fluor® 488 (10 µM) and incubated at 37 °C for 30 minutes. 3x105 Env protein-
expressing HEK293T-cells were seeded in supplemented RPMI-1640 medium in a 4-chambered 35 mm dish 
and allowed to settle overnight. The cells were washed with 1x PBS twice before being incubated with 2 µg of 
protein in 100 µL of 1x PBS for 30 minutes on ice. The cells were then stained with Hoechst 33342 (1 µg/mL) 
in supplemented-free media for 10 minutes. Subsequently, the cells were washed twice with 1x PBS before 
being viewed using the Zeiss LSM 880 confocal microscope together with ZEN software (Zeiss, South Africa).  
A) SNAP-Surface® Alexa Fluor® 488 -conjugated J3-SNAP. B) Hoechst 33342 nuclear stain. C) merge 
of SNAP-Surface® Alexa Fluor® 488 and Hoechst 33342. D) bright light image. 
 
3.2. Development of J3-ETA 
Toward the aim of generating the expression construct pMT-J3-ETA, plasmid DNA was 
isolated from DH5α E. coli cells. Glycerol stocks of DH5α E. coli cells containing pMT-H22-
ETA were inoculated into kanamycin-supplemented (50 µg/mL) LB agar, incubated overnight 
and subsequently lysed for plasmid isolation by alkaline-lysis method (as described in Chapter 
2.2.1.2). The isolated DNA was digested by SfiI and NotI restriction endonucleases (as 
described in Chapter 2.2.1.4) to generate 5’ and 3’ overhangs compatible with those generated 
in J3 using the same restriction endonucleases. The digestion fragments were separated by 
agarose gel electrophoresis (Figure 3.11). Undigested pMT-H22-ETA (Figure 3.11 C - lane 1) 
resulted in bands above 10 kb. The SfiI and NotI linearized controls (Figure 3.11 C lanes 2 and 
3) produced single bands between 6.0 kb and 8.0 kb. Double bands of plasmid vector pMT-
H22-ETA digested with both SfiI and NotI were observed at approximately 7.0 kb and, more 
significantly, at approximately 700 bp. The band at 7.0 kb was thought to be the plasmid vector 
without H22 and the band at 700 bp was believed to be the H22 (SfiI-NotI) fragment that was 




Figure 3.11: Construction of pMT-J3-ETA by PCR amplification of J3 and endonuclease digest of pMT-
H22-ETA. 3 µg of pMT-H22-ETA was digested using 1000 U/mL SfiI and NotI restriction endonucleases for 
3 hours at 50 °C and overnight at 37 °C respectively. 50 µL of digest product was mixed with 1:6 dilution of 
Gel Loading Dye, Purple (6X) [NEB - #B7024S] immediately before being loaded onto 1.2 % agarose gels 
and run at 120 V for 1 hour before being viewed under blue light excitation (470 nm). UD – undigested control. 
NotI/SfiI - single-enzyme digest control. DD, double enzyme digest. MW – molecular weight marker. 
The J3 (SfiI-NotI) insert and the plasmid vector pMT-ETA were then ligated using their 5’-
phosphorylated and 3’-hydroxylated compatible ends generated through SfiI + NotI restriction 
endonuclease digestion. For this reaction, 9 ng and 14 ng of J3 were ligated to using T4 DNA 
ligase 50 ng of pMT-ETA in a 3:1 and 5:1 insert to vector molar ratio respectively (as described 
in Chapter 2.2.1.6). The ligation reaction product, pMT-J3-ETA was transformed into 
chemically competent DH5α E. coli cells before being grown on LB-agar plates supplemented 
with kanamycin (50 µg/mL) overnight at 37 °C (as described in Chapter 2.2.1.7). A vector + 
ligase control was included as a negative control that lacks the insert J3 and hence has linearized 
plasmid. Nevertheless, we observed a CFU of 3.8 x 103 in the negative control (Figure 3.12 A). 
The CFU for the 3:1 (Figure 3.12 B) and 5:1 (Figure 3.12 C) test samples were approximated 
4.32 x 104 and 6.88 x 104 respectively.  
A B 
pMT-J3-ETA 












Figure 3.12: LB-Agar plates of DH5-α E. coli cells transformed with pMT-J3-ETA. 
The recombinant plasmid was generated through ligation of various insert-to-vector molar rations [8 ng (B, 
1:3), 14 ng C, 1:5)] of J3 to 50ng of pMT-ETA plasmid vector to generate pMT-J3-ETA. 5 µL ligation product 
was then transformed into 50 µL competent DH5-α E. coli cells which subsequently grown on LB-agar plates 
supplemented with 50 ug/mL of kanamycin. A) kanamycin-containing LB-agar plate with DH5-α E. coli cells 
transformed with linearized plasmid vector. B-C), kanamycin-supplemented LB-agar plates with DH5-α E. coli 
cells transformed with pMT-J3-ETA. 
 
To verify the identity of the plasmids in Figure 3.11 B and C, four colonies were selected at 
random from each plate and inoculated into 5 mL LB-broth media supplemented with 50 
µg/mL kanamycin. The inoculated 5 mL cultures were incubated to grow overnight at 37 °C, 
after which 4 mL of the 5 mL culture was used for pMT-J3-ETA plasmid DNA isolation. 
Isolated plasmid (pMT-J3-ETA) was used for restriction endonuclease mapping using PvuII, 
and pMT-H22-ETA was used as a control. For restriction mapping,100 µg of the plasmid 
(pMT-J3-ETA and pMT-H22-ETA) was digested using 1000 U/mL of PvuII at 37 °C for 2 
hours before being analysed by agarose gel electrophoresis. SnapGene® software (v.5.0.8, 
GSL Biotech LLC, USA) was used to simulate an agarose gel depicting the DNA fragments 
resulting from the PvuII restriction endonuclease digest of either pMT-H22-ETA or pMT-J3-
ETA (Figure 3.13 A). The simulation predicted that pMT-H22-ETA digested using PvuII 
resulted in four fragments of sizes 4730 bp, 1599 bp, 999 bp and a band below 0.5 kb. The 
simulation predicted that pMT-J3-ETA digested using PvuII resulted in two fragments of sizes 
5998 bp and 999 bp. In accordance with the simulation, pMT-H22-ETA digested using PvuII 
resulted in 4 bands at the approximate size of the simulated gel (Figure 3.13 B). However, 
although all four of the 3:1 and three of the 5:1 insert-to-vector ratio colonies corresponded to 
the SnapGene ® simulation, one of the 5:1 colony (Figure 3.13 B – lane 8) resembled pMT-
H22-ETA control instead of pMT-J3-ETA. A second verification step was used to confirm that 
the cloning of pMT-J3-ETA had been successful. For this, the remaining 1 mL of cultures 
prepared from select colonies which most resembled the pMT-J3-ETA SnapGene® simulation 
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were each inoculated into a 50 mL LB-broth supplemented with 50 µg/mL of kanamycin and 
incubated at 37 °C overnight. Plasmid DNA was isolated by alkaline lysis method (as described 
in Chapter 2.2.1.2) and subjected to Sanger sequencing. (Figure 3.13 C) depicts the alignment 
of the Sanger sequences to the consensus sequence, confirming that the recombinant plasmid 









Figure 3.13: Sequence confirmation by restriction endonuclease mapping of the recombinant plasmid. 
A) SnapGene® software (v.5.0.8, GSL Biotech LLC, USA) was used to simulate an agarose gel of pMT-H22-
ETA and pMT-J3-ETA digested using PvuII. B) 3 µg pMT-H22-ETA, pMT-J3-ETA was digested using 1000 
U/mL of restriction endonuclease PvuII at 37 °C overnight. 50 µL of restriction endonuclease digest product 
was mixed with 1:6 dilution of Gel Loading Dye, Purple (6X) [NEB - #B7024S] and run on 1.2 % agarose gel 
at 120 V for 1 hour before being visualised under blue light excitation (470 nm). C) Alignment of J3-ETA 





Chapter 4: Discussion and Conclusion 
4.1 Purpose of this study 
Since the discovery of HIV in 1984 and its identification as the causative agent of AIDS, great 
strides have been made to combat this pandemic. The use of cART to strategically target 
specific stages in the pathogenesis of HIV, including entry, reverse transcription, integration, 
and protease processing, has led to a reduction in the viremia of infected people to undetectable 
levels [2], [3] ,[102 -120]. cART has reduced the global infection and fatality rate, allowing 
infected people to lead relatively normal lives [4] [7] [8]. The use of cART allows the 
restoration of immune function and prevents progression to AIDS, thus negating the 
susceptibility of HIV infected people to opportunistic infections such as MTB, OPC, and PCP 
[79-101]. A cure for HIV, however, remains elusive owing to its establishment of viral 
reservoirs in long-lived memory CD4+T-cells in the early stages of infection. Following the 
cessation of cART, a rapid relapse of viremia occurs. Multiple studies have proposed that a 
cure for HIV may lie in a combinatory approach comprised mainly of latency-reversing agents, 
combination antiretroviral therapy, and the targeted elimination of HIV-infected immune cells 
[147], [177], [178]. The use of antibody-based therapies has taken a lead in cancer therapy with 
more than one hundred antibody-based therapeutics being approved for clinical application in 
recent decades [178]-[180]. ITs composed of antibody targeting moieties and protein toxins 
have demonstrated antitumor effects prompting approval for clinical use [181]-[184],[190]. For 
instance, Moxetumomab pasudotox is an IT composed of ETA and anti-CD22 monoclonal 
antibody and received approval for clinical application against hairy cell leukaemia [191]. 
Lessons can be learnt from such ITs to inform the design of potential therapeutics against HIV. 
Anti-HIV antibodies that can be used against HIV have previously been described [197], [198], 
[237], [238]. The use of an antibody targeting domain for an HIV gp120-specific antibody 
domain is a promising therapeutic strategy. These therapeutics have, however, shown poor 
efficacy in phase 1 clinical trials. This has been attributed to the affinity of the antibody to 
gp120 [193], [199], [239]–[241]. Interestingly, a highly potent antibody, J3, was described and 
demonstrated high specificity for HIV gp120, neutralising 96 % of the HIV-strains tested [208]. 
This study, therefore, aimed to understand whether a J3-ETA IT can be used for the selective 
elimination of HIV-infected CD4+ T-cells. To investigate, a reporter protein, J3-SNAP, was 
developed in order to validate whether: (1) J3 can bind to cell-surface Env protein, and  
(2) functional J3 protein recombinantly fused to the reporter protein SNAP-tag can be 
expressed in the periplasmic space of E. coli. Once functional J3-SNAP protein produced in 
67 
 
E. coli would be produced and shown to bind to cell-surface Env protein, the development and 
expression of J3-ETA could begin.  
4.2 In silico design of recombinant plasmid 
Bioinformatic tools play a critical role in the design of antibody-based fusion proteins and ITs. 
These tools are used to analyse antibody sequences obtained from public databases such as 
Protein Data Bank, Uniprot, and patents [242], [243]. The analysis typically involves the use 
of web-based tools such as IMGT V-QUEST, and IgBLAST to identify the region of the 
antibody being analysed by sequence alignment to germline sequences [242]–[244]. For 
instance, McCoy et al. (2012) used IMGT V-QUEST for the alignment of J3 to the human 
germline sequence and was able to verify that J3 was a V gene and identified the FR and CDR 
regions [208]. Similarly, this study sourced the sequence for J3 from patent no. WO 
2013/036130 AI and performed a sequence alignment to the germline sequence IgHV3, further 
validating that this was a V gene, and identified intact FR and CDR regions. These findings 
were verified by IgBLAST. The sequence for the plasmid vector of interest is then obtained 
and analysed for restriction endonuclease sites to facilitate the insertion of foreign genes into 
specific regions of the plasmid [245]. The pET plasmid vector is commonly used for the 
expression of recombinant proteins in E. coli [246]. pMT, a derivative of pET, has been used 
for the expression of the recombinant IT H22(scFv)-ETA [247]. In this study, SnapGene® 
software was used to virtually clone the bacteria-optimised DNA sequence for J3, following 
the insertion of appropriate restriction endonuclease sites, into the pMT plasmid vector. The 
H22(scFv) was replaced by J3 to generate J3-ETA and ETA was then replaced with SNAP-tag 
to generate J3-SNAP. Protein parameters such as the pI and the MW are assessed using web-
based tools such as the “ExPASY Compute pI/MW” tool, as was done in this study [248]–
[251].  
4.3 Molecular cloning of pMT-J3-SNAP 
Described procedures for the generation of recombinant plasmids include the amplification of 
the gene to be inserted into the plasmid by PCR. The gene is then visualized on an agarose gel, 
purified and digested with the appropriate restriction endonucleases to facilitate site-directed 
inclusion into the plasmid to be used for protein expression. DNA ligase is then used to insert 
the gene of interest into the desired vector thus creating a recombinant plasmid [252]–[254]. 
For instance, Kampmeier et al. (2009) described the development of scFv-SNAP recombinant 
plasmids where SfiI + NotI were used to introduce the protein ligand, and XbaI + BlpI were 
used to introduce SNAP-tag. A similar protocol was described by Hussain et al. (2019) and 
68 
 
was thus adopted for the development of pMT-J3-SNAP. J3 (SfiI + NotI) was ligated into a 
pre-existing pMT-SNAP plasmid. Successful molecular cloning was confirmed by restriction 
endonuclease mapping and Sanger sequencing. Interestingly, a deletion was observed in the 
Sanger sequences and was, upon investigation, identified to be due to an error in the synthesis 
of SNAP-tag. Site-directed mutagenesis by overlap extension (OE) PCR has been used to 
create insertions and deletions in DNA sequences. This is a two-step procedure that involves 
the use of two overlapping primers specific for the site to be mutated, and two primers flanking 
both sides of the gene to be mutated (Figure 3.5). First, two amplicons are generated by the 
reverse site-specific primer and the forward gene-specific primer, and the second amplicon is 
generated by the forward site-specific primer and the reverse gene-specific primer in a separate 
reaction. The two amplicons are then sewed together using the gene-specific primers [255]–
[258]. This protocol was used to insert the deleted nucleotide in the J3-SNAP gene. The OE-
PCR-generated J3-SNAP was then digested by SfiI + BlpI before being ligated into the pMT 
plasmid to generate pMT-J3-SNAP. The alignment of the OE-PCR-mutated Sanger sequences 
to the consensus sequence confirmed successful repair of the mutation and as such, the 
successful development of pMT-J3-SNAP recombinant plasmid. 
4.4 Protein expression 
As a host of expression, mammalian expression systems are preferred because they induce 
post-translational modification and correct protein folding of recombinant proteins. 
Furthermore, HEK293T cells are capable of secreting recombinant proteins into the medium, 
making the harvesting of protein easier, and removing the need for cell lysis for protein 
extraction [259]–[261]. As a result, the production of SNAP-tag fusion proteins has been 
carried out mainly in mammalian cells. The expression antibody-based SNAP-tag fusion 
proteins in HEK293T cells, secreted into the medium and purified by the interaction of an N-
terminal poly (His)-tag with IMAC column, has been well reported [252], [253], [262], [263]. 
Functionality was demonstrated by BG-modified fluorophore conjugation to SNAP-tag, and 
antibody binding to the target antigen [252], [253]. The relatively high cost of production in 
HEK293T cells means that more cost-effective measures may prove beneficial. Fortunately, 
Djender et al. (2014) reported the expression of fully-functional SNAP fusion protein in 
bacteria. The study reported successful cytoplasmic expression of poly (His)-tagged anti-
HER2(VHH)-SNAP-fusion protein which was subsequently purified by IMAC. Djender et al. 
(2014) also reported that the periplasmic expression of SNAP-tag fusion proteins resulted in 
poorly folded and aggregated protein [264]. However, Barth et al. (2000) demonstrated that 
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difficult-to-express proteins can be expressed in the periplasmic space under osmotic stress 
conditions, aided by compatible solutes. The rationale being that cell stress response 
mechanisms such as the induction of heat shock proteins, together with compatible solutes 
which were shown to protect the proteins of interest from degradation, aggregation and 
misfolding; and increase the production of otherwise difficult to express proteins by up to one 
thousand fold [224]. The VHH antibody format, due to its small size, offers some advantages. 
For instance, compared to larger antibody formats, it has a less complex tertiary structure, has 
fewer disulphide bridges and has thus been produced in E. coli [264]. With this taken into 
consideration, and preliminary data from colleagues within our research group demonstrating 
successful periplasmic expression of SNAP-tag fusion proteins, this study set out to express 
J3-SNAP in the periplasmic space of E. coli BL21 DE3 under osmotic stress conditions in 
the presence of compatible solutes.  
Despite the rarity of literature reporting on the successful periplasmic expression of SNAP-tag 
fusion proteins, and lack of means to predict the quality of protein that can be produced under 
such conditions, successful expression of J3-SNAP was achieved. This was demonstrated by 
the presence of strong protein bands at approximately 32 kDa on the SDS-PAGE gel and 
verification by Western blot using a rabbit anti-His tag primary antibody and a goat anti-rabbit 
horseradish peroxidase-conjugate secondary antibody. Further optimisation of the protocol is 
required due to the protein yield and the purity obtained being comparably lower than that 
obtained by previous studies of periplasmic expression by osmotic stress by Barth et al. (2000), 
and cytoplasmic expression of SNAP-tag fusion protein by Djender et al. (2014) [224], [264]. 
The SDS-PAGE and Western blot showed a contaminant band at approximately 72 kDa, and 
what appears to be degradation products. The misfolding of protein is known to lead to protein 
degradation in the periplasmic space [265], [266]. To address protein misfolding, other studies 
reduced the IPTG concentration to prevent overexpression which may lead to aggregation and 
reduced the temperature at which the expression was carried out to as low as  20 °C [264], 
[267]–[269]. A second purification step such as size exclusion chromatography should be 
applied as it has been shown to increase the purity of recombinant proteins expressed in the 
periplasmic space [224], [270], [271]. Nevertheless, this study reports the successful 
periplasmic expression of J3-SNAP protein under osmotic stress in the presence of 
compatible solutes.  
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4.4 Protein functionality 
To assess protein functionality, J3-SNAP was conjugated to SNAP-Surface® Alexa Fluor® 
488 before being incubated with Env-expressing HEK293T-cells in vitro. HEK293T-cells 
transfected with recombinant HIV Env are typically developed and used as pseudoviruses in 
the development of vaccines. To achieve this, the HEK293T-cells are seeded and allowed to 
reach the desired confluency. Thereafter, plasmid DNA, typically pcDNA, is mixed with a 
transfection reagent such as PEI to form a complex. The complex is then added to cells and 
allowed to carry the DNA into the cells by endocytosis. Medium is then changed after six hours, 
and the cells are harvested for analysis after 48 hours [272], [273]. In this study, the same 
protocol was followed using the plasmid pcDNA-TOPO-gp120, and Env expression was 
confirmed by SDS-PAGE and Western blot. β-actin was used as a loading control and to show 
that where no HIV Env signal was observed, it was due to lack of expression rather than the 
absence of cells. The presence of a signal at 160 kDa (gp120 + gp41) confirmed successful 
cloning and expression of HIV Env protein. However, uncleaved gp160 suggested 
incomplete processing of the recombinant protein and this is known to significantly reduce its 
presence at the cell surface and its incorporation into budding virions [274]–[277]. 
Furthermore, the transient expression of the HIV Env proten in HEK294T cells has previously 
been shown to result in a poorly cleaved product with reduced membrane incorporation [278]. 
For the purposes of this study, however, less than optimal membrane expression was acceptable 
as the goal was to determine whether or not J3-SNAP could bind to the HIV Env protein. 
Therefore, these cells were then used to detect the antigen-binding of J3 to the Env protein. 
Cell-surface labelling of antigen-positive cells using SNAP-tag-based antibody fusion proteins 
is preceded by the conjugation of the SNAP-tag to a substrate such as SNAP-Surface® Alexa 
Fluor® 488. Protocols described by Kampmeier et al. (2009) and Hussain et al. (2019) describe 
protein labelling as follows; SNAP-tag-based protein is incubated with at least two-fold molar 
excess BG-modified substrate at room temperature in the dark for two hours. Thereafter, a 
desalting column may be used to remove excess dye and SDS-PAGE can be used to validate 
successful conjugation through UV transillumination. Thereafter, 1 µg the fluorophore-
conjugated protein is then incubated with the antigen-presenting cells on ice for 30 minutes. 
The cells are then washed to remove unbound stain protein and counterstained using Hoechst 
33342 nuclear stain before being analysed by microscopy [252], [253]. In this study, the above-
described protocol was used but with some modifications. Firstly, 2 µg of labelled protein was 
used instead of 1 µg to compensate for the poor purity which meant that less J3-SNAP was 
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present in the protein sample. Secondly, confirmation of protein conjugation by SDS-PAGE 
was omitted as cell-surface labelling can itself act as confirmation of SNAP-tag activity. A 
negative control was omitted from the results due to poor image quality. Nevertheless, the 
green fluorescence around the cell membrane suggested the following; (1) That SNAP-tag was 
functional as it was able to react with the SNAP-Surface® Alexa Fluor® 488, and (2) J3 was 
able to bind to recombinant Env protein on the surface of HEK293T-cells in vitro. There was, 
however, not much green fluorescence around the surface of the HEK293T-cells. This may 
have been due to the following; (1) a low number of recombinant Env protein proteins on the 
surface of the HEK293T-cells; (2) the previously mentioned proteolytic degradation or possible 
misfolding of protein which may have led to a reduction in the activity of the J3, SNAP-tag, or 
both; and (3) membrane blebbing evidenced by the presence of a blue DNA stain around the 
surface of the HEK293T-cells may indicative of an apoptotic cell [279]–[281]. Taken together 
with the rounded morphological appearance of the cell, as opposed to their native spindle-
shaped morphology, this was indicative that the cells may have been undergoing apoptosis 
[279]–[281]. Hypothermia has been known to cause cell death in mammalian cells [282], [283]. 
In this experiment, the incubation of SNAP-Surface® Alexa Fluor® 488-conjugated J3-SNAP 
with the Env protein-expressing HEK293T-cells was carried out on ice. Thereafter, the cells 
were kept on ice before being viewed under confocal microscopy, possibly causing 
hypothermic stress. Though the cells are kept on ice to prevent protein internalization upon 
membrane binding, successful membrane binding has been demonstrated at room temperature 
[284]. With the limitations of this experiment considered, the results remain indicative of cell 
surface binding of Env-specific J3-SNAP protein conjugated to SNAP-Surface® Alexa Fluor® 
488 thereby suggesting functionality of the antibody domain and reported domain of the 
developed fusion protein. 
4.5 Development of J3-ETA 
The elimination of latently infected HIV reservoir cells is an essential step in achieving a cure 
for HIV. The use of antibody ITs targeting virus antigens on diseased cells is a promising 
avenue currently being pursued [237], [285]. For instance, Spiess et al. (2015) published data 
on the use of an ETA-based fusion protein targeting chemokine receptors on human 
cytomegalovirus (HCMV) infected cells, which showed anti-HCMV potency both in vitro and 
in vivo [286]. ETA-based VHH ITs have been used to kill herpes simplex virus 2 (HSV-2) 
infected cells [287]. This study, therefore, aimed to design and develop an ETA-based IT using 
the highly potent broadly specific VHH antibody, J3. Following the confirmation of the 
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periplasmic expression and functionality of J3-SNAP, the next step involved the development 
of J3-ETA. This began with the generation of the pMT-J3-ETA recombinant plasmid. This 
involved removal of H22 from the pre-existing recombinant plasmid pMT-H22-ETA using 
restriction endonucleases, followed by replacement of H22 with J3 using T4 DNA ligase. pMT-
J3-ETA was subsequently transformed into competent E. coli DH5α competent cells. 
Kanamycin was used to select for positive clones, which were subsequently confirmed by 
restriction endonuclease mapping and Sanger sequencing. This experiment, therefore, 
demonstrated the successful construction of the pMT-J3-ETA recombinant plasmid. 
 
 
4.6 Conclusion and future perspectives 
The data reported herein suggest that SNAP-tag based fusion proteins previously 
expressed in a poorly folded state in the periplasmic space can be expressed and exhibit 
functionality when expressed under compatible solute-guided osmotic stress conditions. 
Bacteria is the most widely used and cost-effective means of producing recombinant proteins 
and is scalable to meet high quantity demands [288]. The periplasmic space is often known to 
produce functional antibody formats due to the capacity to form disulphide bonds. The 
periplasm is also free from several bacterial proteases, and the harvesting of protein is easier 
in the periplasm [222], [289], [290]. The expression of J3-SNAP in the periplasm, therefore, 
presents an alternative to the previously described cytoplasmic expression of SNAP-tag-based 
fusion proteins [264]. Furthermore, preliminary binding data depicted this study suggests that 
J3 can be used to target Env-expressing cells in vitro. Upon learning the binding capacity of 
J3, the IT J3-ETA was developed, and forms part of an ongoing study aimed at developing 
anti-HIV ITs.  
Future perspectives will be focused on the following; (1) The optimization of the periplasmic 
expression of J3-SNAP; (2) The periplasmic expression and characterisation of J3-ETA; and 
(3) Validation of the binding of J3-SNAP and J3-ETA against HEK293T-cells expressing 
recombinant Env protein from various strains of HIV. There is a growing resistance to current 
antiretroviral therapy suggesting that other therapeutic strategies need to be explored at 
accelerated rate. For instance, in 2018 it was reported that approximately 15 % of infected 
people in South Africa were resistant to one or more ARVs and this number is projected to 
exceed 30 % by 2030 [291]. This highlights the potential for broadly specific anti-HIV 
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antibodies such as J3. The collaboration with Dr Zenda Woodman (University of Cape Town, 
South Africa) is crucial to our study as it will allow us access to various Env protein isoforms 
from South African patients. Given the disproportionate burden of HIV in South Africa, we are 
very interested in developing an anti-HIV IT capable of eliminating cells infected with various 
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